{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to escitalopram for individuals with the HTR2A rs7997012 A allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered escitalopram efficacy in patients with the HTR2A rs7997012 A allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nadolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pindolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pindolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for cisplatin in pediatric patients based on their COMT genotype to mitigate hearing loss?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of ciprofloxacin's inhibition of the CYP1A2 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the efflux and disposition of etoposide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using paroxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing hypertension with venlafaxine in patients with specific ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse cardiovascular events with clopidogrel in patients with loss-of-function CES1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myopathy when gemfibrozil is co-administered with a statin in a patient with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rosuvastatin in pediatric patients with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for rosuvastatin adjusted for ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for celecoxib recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for celecoxib based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of hydrochlorothiazide (HCTZ) for a patient with the ADD1 Gly460Trp polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvoxamine in adolescents with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for fluvoxamine in adolescent patients, adjusted for HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ADRB2 haplotypes correspond to bronchodilator response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which methylene blue causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methylene blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of methylene blue-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of calcitriol for a patient with a specific variant in the vitamin D receptor (VDR) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of desvenlafaxine in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for desvenlafaxine in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for buprenorphine in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for buprenorphine in opioid use disorder patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of fosphenytoin-induced toxic epidermal necrolysis (TEN) in an HLA-B*15:02 carrier?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for TEN in HLA-B*15:02 carriers taking fosphenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should cromolyn sodium dosing be adjusted for a patient with a genetic variant affecting mast cell stabilization?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target urinary concentration for fosfomycin based on the MurA genotype of the infecting organism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target blood eosinophil count reduction for a mepolizumab-treated patient based on their IL5RA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for diclofenac use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for diclofenac in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for duloxetine in adolescents with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for duloxetine in adolescent patients, adjusted for SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which UGT1A9 genotypes are associated with altered propofol glucuronidation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FCGR3A genotypes correlate with ocrelizumab treatment response in primary progressive multiple sclerosis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypersensitivity reactions with probenecid in individuals with specific OAT1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolic pathway of metformin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the POR genotype correlate with overall CYP3A activity and tacrolimus dose requirements?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fentanyl dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for fentanyl in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fludarabine dosing be adjusted for a patient with a specific variant in a nucleoside transporter gene like SLC28A1?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the pharmacokinetics of rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of ABCG2's role as an efflux transporter affecting rosuvastatin disposition.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should lithium dosing be adjusted for a patient with a GADL1 gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking tenoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using tenoxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with irbesartan in individuals with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is mesalazine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mesalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for mesalazine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking hydrocodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for hydrocodone in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should hydrocodone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for hydrocodone based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which UGT1A9 genotypes are associated with altered MPA glucuronidation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for saxagliptin in type 2 diabetes patients with a known CYP3A4 variant and moderate renal impairment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neuropsychiatric events with montelukast in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma pemetrexed concentrations based on MTHFR genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation with erythromycin in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of acetylcholinesterase (ACHE), the target of donepezil, and how might its variants alter drug binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for paroxetine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for paroxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for endoxifen, the active metabolite of tamoxifen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tamoxifen\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf\", \"Content to Search\": \"Therapeutic plasma concentration range for endoxifen\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for dasatinib in CML patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of peripheral edema for nifedipine users with decreased CYP3A4 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ruxolitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of codeine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in converting codeine to its active metabolite, morphine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of meloxicam for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for meloxicam in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the absolute contraindication for dofetilide based on specific KCNH2 genotypes associated with Long QT Syndrome Type 2?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 rapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rabeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions corresponding to the CYP2C19 rapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma desethylamiodarone in a patient with a specific CYP2C8 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tramadol in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing recommendations or contraindications for tramadol in lactating mothers with a CYP2D6 UM phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 variants and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended rosuvastatin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for rosuvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe neutropenia with irinotecan in patients homozygous for the UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to sumatriptan in individuals with high-activity MAOA variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluoxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma pramipexole concentrations in a patient with a high-function SLC22A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of adverse effects to fluvoxamine for individuals with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for increased adverse effects of fluvoxamine in patients with the SLC6A4 S/S genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for fentanyl in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking norfloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"norfloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with norfloxacin use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a documented increased risk of adverse effects from nortriptyline in CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using nortriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for tacrolimus in a patient with the ABCB1 3435C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C9 to the overall clearance of aspirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's role in aspirin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of fluoxetine in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluoxetine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering methoxyflurane to a patient with a pathogenic RYR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for methoxyflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer for flecainide therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should acebutolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for acebutolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended propranolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for propranolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ondansetron for a patient with the ABCB1 G2677T/A polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for dibekacin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dibekacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for dibekacin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of nebivolol for a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of adverse effects to fluoxetine for individuals with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for increased adverse effects of fluoxetine in patients with the SLC6A4 S/S genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse events in a CYP2D6 poor metabolizer taking trimipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of adverse events in CYP2D6 poor metabolizers on trimipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rosiglitazone in patients with a CYP2C8*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of CNS side effects with efavirenz in individuals who are CYP2A6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking fluvoxamine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma alfentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for alfentanil stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in phenytoin metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Function of CYP2C9 enzyme in the metabolic pathway of phenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in individuals with HMGCR variants taking simvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of first-dose hypotension for ramipril users with the ACE DD genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atenolol in patients with heart failure and a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for atenolol in heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of nadolol in patients with high-activity GRK4 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C9 genotypes map to metronidazole clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of apixaban?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for ruxolitinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for methotrexate in a patient with the MTHFR A1298C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hallucinations and somnolence with ropinirole in individuals with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myelosuppression with mitomycin C in individuals with the NQO1*2 allele (low activity)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for enasidenib in a patient with a specific UGT1A1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested serum potassium level to monitor in an amiloride-treated patient based on their SCNN1A genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing a positive antinuclear antibody (ANA) test with procainamide in NAT2 slow acetylators?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT2B7 enzyme in the glucuronidation of valproic acid?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role as the primary metabolic pathway for vortioxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of fenofibric acid in a patient with a low-activity UGT1A9 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sonidegib in basal cell carcinoma patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to chloramphenicol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloramphenicol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters (hemoglobin, reticulocyte count) in G6PD deficient individuals after chloramphenicol administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for lornoxicam recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for lornoxicam based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for haloperidol in geriatric patients with a CYP2D6 decreased function allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of desvenlafaxine in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for desvenlafaxine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 normal metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of pitavastatin for a patient with a UGT1A3 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended simvastatin dose for an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for simvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pravastatin in pediatric patients with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for pravastatin adjusted for ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of fluoxetine in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluoxetine in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for colchicine in patients with renal impairment and a known low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of malaria prophylaxis failure with proguanil in individuals who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma indapamide concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of atomoxetine for a patient with a CYP2D6 gene duplication and comorbid anxiety?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes are classified as intermediate metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tamoxifen\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for pindolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Cereblon (CRBN) and how do its mutations affect the binding and activity of pomalidomide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 haplotypes correspond to linagliptin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of nadolol in patients with the ADRB2 Gln27Glu polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of dizziness with memantine in individuals with specific SLC22A2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which UGT1A1 diplotypes correspond to the intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atazanavir\", \"Gene Name\": \"UGT1A1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf\", \"Content to Search\": \"List of UGT1A1 diplotypes that define the intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of interstitial lung disease with osimertinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the mechanism of action of vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for vortioxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for lenalidomide in myelodysplastic syndromes based on CRBN genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to pegloticase?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pegloticase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after pegloticase administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of azathioprine for a patient with a GSTM1-null genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfamethoxazole / trimethoprim?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfamethoxazole / trimethoprim\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sulfamethoxazole / trimethoprim administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of mometasone for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking flurbiprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using flurbiprofen.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hand-foot syndrome with capecitabine in patients with high-activity CES2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with flurbiprofen in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using flurbiprofen.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 gene product in the context of propranolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for propranolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the metabolism of escitalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's primary role in the metabolic pathway of escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should lenalidomide dosing be adjusted for a patient with a specific variant in the CRBN (cereblon) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of orthostatic hypotension with tamsulosin in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should eltrombopag dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using nebivolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of crizotinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 gene product in the context of bisoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 receptor in the mechanism of action of carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe flushing with niacin in individuals with high-expression HCAR2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of gefitinib for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to fentanyl clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma fluvastatin concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvastatin in CYP2C9 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Vascular Endothelial Growth Factor A (VEGF-A) and how might its genetic variants alter response to anti-VEGF therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for peginterferon alfa-2b treatment duration in HCV genotype 1 patients based on IFNL3 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Guidance on peginterferon alfa-2b treatment duration for HCV genotype 1 patients stratified by IFNL3 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in extruding phenytoin from the brain?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target minimum inhibitory concentration (MIC) for amoxicillin based on the PBP genotype of the infecting organism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma felodipine concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of fecal fat excretion for an orlistat-treated patient based on their PNLIP genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended citalopram dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for citalopram in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for vardenafil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfadimidine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadimidine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sulfadimidine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for codeine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for lomustine based on the MGMT methylation status of the tumor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of albuterol for a patient with the ADRB2 Arg16Gly polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should dutasteride dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should risperidone dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for acebutolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking high-dose vitamin C?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin c\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with high-dose vitamin C use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fosfomycin dosing be adjusted for a patient with a specific variant in the MurA gene of the infecting bacteria?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the paraoxonase 1 enzyme (PON1) in the metabolic pathway of prasugrel?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiotoxicity with carfilzomib in individuals with genetic predispositions to heart failure?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested level of STAT1 phosphorylation to monitor in an interferon alfa-treated patient based on their genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma cetirizine (active metabolite) concentrations in a hydroxyzine-treated patient who is a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FDPS genotypes correlate with zoledronic acid efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for cyclosporine in pediatric transplant recipients based on their CYP3A5 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rasburicase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of the inactive metabolite dFdU in a gemcitabine-treated patient with a high-activity CDA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'high-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for venlafaxine in an adolescent with the SLC6A4 s/s genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for venlafaxine in adolescents based on SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CRBN genotypes correlate with lenalidomide resistance phenotypes in multiple myeloma?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of renal toxicity with pamidronate in individuals with genetic predispositions to kidney disease?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should remifentanil dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for remifentanil in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCG2 genotypes correlate with imatinib response phenotypes in chronic myeloid leukemia (CML)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do IL5RA genotypes correlate with mepolizumab efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of losartan for a patient identified as a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for atenolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neuropsychiatric events with montelukast in patients with CYP2C8 poor metabolizer status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in exposure to nabumetone's active metabolite in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on nabumetone's active metabolite exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse events for a CYP2D6 poor metabolizer taking nortriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of adverse events in CYP2D6 poor metabolizers on nortriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nebivolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nebivolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for venetoclax in CLL patients with known CYP3A4 variants, especially during co-administration with strong CYP3A4 inhibitors?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP2C9's role in pravastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for methoxyflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for methoxyflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of levomethadone therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for levomethadone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for osimertinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nadolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC12A1 genotypes correlate with diuretic resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma zaleplon concentrations in a patient with a high-activity AOX1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target intracellular concentrations of doxorubicin in cardiac tissue based on a patient's SLC22A16 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking codeine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for codeine in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ceftriaxone dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for streptomycin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"streptomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for streptomycin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which high-dose vitamin C causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin c\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of high-dose vitamin C-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Glutathione S-transferase Pi 1 (GSTP1) enzyme in the detoxification of carmustine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for betaxolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pindolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for pindolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended propranolol dose for an individual with the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for propranolol based on ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 intermediate metabolizer for sirolimus therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP2C9 poor metabolizers using rosuvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering halothane to a patient with a pathogenic CACNA1S variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for halothane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the alpha-4 integrin (ITGA4), the target of natalizumab, and how might its variants alter drug binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for pembrolizumab based on a patient's germline PDCD1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to omalizumab in individuals with FCER1A variants that alter IgE binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for larotrectinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for desvenlafaxine in adolescents with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for desvenlafaxine in adolescent patients, adjusted for SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nevirapine in pediatric HIV patients based on their CYP2B6 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for galantamine in elderly Alzheimer's patients with known CYP2D6 and CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested level of B-cell depletion for an ocrelizumab-treated patient based on their FCGR3A genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ondansetron concentrations in a CYP1A2 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypokalemia with chlorthalidone in individuals with gain-of-function variants in the NCC transporter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for glyburide in a diabetic patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glyburide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for glyburide in G6PD deficient patients with type 2 diabetes.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CHRM1/CHRM3 genotypes correlate with the efficacy and safety of tiotropium?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SV2A genotypes correlate with levetiracetam response phenotypes in epilepsy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of sertraline in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for sertraline in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of zoledronic acid for a patient with a specific variant in the FDPS (farnesyl diphosphate synthase) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should atenolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for atenolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should famotidine dosing be adjusted for a patient with a low-function MATE1 (SLC47A1) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should amiodarone dosing be adjusted for a CYP2C8*3 carrier?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should panitumumab dosing be adjusted for a patient with a specific NRAS gene mutation in their tumor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A3 genotypes map to pitavastatin glucuronidation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define ABCG2 normal function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the ABCG2 normal function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for temozolomide based on the MGMT methylation status of the tumor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which primaquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"primaquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of primaquine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SULT2A1 enzyme in the sulfation and clearance of abiraterone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for cefepime in a patient based on their genetic risk score for neurotoxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target TSH level for a levothyroxine-treated patient based on their DIO2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for halothane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for halothane in the context of RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of angioedema from lisinopril in individuals with the ACE II genotype compared to the DD genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for voriconazole, and what is the role of CYP2C19?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"voriconazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf\", \"Content to Search\": \"Description of voriconazole's metabolism and the specific function of the CYP2C19 enzyme.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of liver function abnormalities with febuxostat in individuals with the ABCG2 Q141K variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using paroxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for atenolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomethadone in children with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for levomethadone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to methylene blue?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methylene blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after methylene blue administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with ranitidine in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bradycardia with nebivolol in CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to hydromorphone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and hydromorphone's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking oxycodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for oxycodone in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with indomethacin in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using indomethacin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe diarrhea with misoprostol in individuals with specific PTGER3 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sotalol in patients with heart failure and the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for sotalol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to chlorpropamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chlorpropamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after chlorpropamide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should esmolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for esmolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypoglycemia with nateglinide in individuals with reduced CYP2C9 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma tropisetron concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of naltrexone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in naltrexone metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of anticholinergic toxicity with desipramine in CYP1A2 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nadolol in elderly patients with heart failure and the GRK5 Leu41 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nadolol in elderly heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in bisoprolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for paroxetine based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma paroxetine concentrations in a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges for paroxetine in CYP2C19 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bleomycin dosing be adjusted for a patient with a BLMH (bleomycin hydrolase) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should desvenlafaxine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for desvenlafaxine based on HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended alfentanil dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for alfentanil in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should milnacipran dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for milnacipran in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nebivolol dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nebivolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for naproxen involving the CYP2C9 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gliclazide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of life-threatening myelosuppression when administering standard-dose thioguanine to a NUDT15 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Quantified risk data for severe toxicity in NUDT15 poor metabolizers using thioguanine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP3A4 in the metabolism of hydroxyzine to cetirizine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 intermediate metabolizer in the context of warfarin dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for meloxicam use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for meloxicam in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for acebutolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the incidence of grade 3 or higher toxicity in DPYD poor metabolizers treated with standard-dose fluorouracil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluorouracil\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Incidence rates of severe toxicity for DPYD poor metabolizers on fluorouracil\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected 6-TGN levels in a TPMT intermediate metabolizer on a standard mercaptopurine dose compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Comparative pharmacokinetic data on 6-TGN levels between TPMT intermediate and normal metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomilnacipran in adolescents with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for levomilnacipran in adolescent patients, adjusted for SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which ciprofloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ciprofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of ciprofloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of lopinavir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for abemaciclib in breast cancer patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered vilazodone response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definitions of HTR2A genotypes and their association with vilazodone efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A16 genotypes correlate with doxorubicin-induced cardiomyopathy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for bisoprolol in elderly patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for bisoprolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the ABCG2 decreased function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sodium nitrite causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sodium nitrite\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sodium nitrite-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for buprenorphine in children with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for buprenorphine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for ertapenem based on a patient's genetic risk score for neurotoxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pindolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for pindolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of amikacin for a patient with the MT-RNR1 m.1555A>G mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tamsulosin dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma erlotinib concentrations in a CYP1A2 rapid metabolizer (e.g., a heavy smoker)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the P-glycoprotein (ABCB1) in the intestinal absorption and clearance of dabigatran?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma esmolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for esmolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the EP3 receptor (PTGER3), a target of misoprostol, and how might its variants alter drug action?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma salicylate concentrations in a patient taking high doses of bismuth subsalicylate based on their UGT1A6 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of indomethacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in indomethacin's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C19 normal metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of nateglinide for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of poor glycemic response to metformin in individuals with ATM gene variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma caspofungin concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pitavastatin dose for a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pitavastatin in CYP3A5 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for tenoxicam recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for tenoxicam based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of fingolimod for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for propranolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for propranolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of methylphenidate for a patient with a specific CES1 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the molecular mechanism by which cromolyn sodium stabilizes mast cells, and are there known genetic modifiers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma levomethadone concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for levomethadone stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected area under the curve (AUC) for lansoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on lansoprazole exposure in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 gene product in the context of esmolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking sufentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of sufentanil in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correlate with the systemic bioavailability of inhaled mometasone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Aldehyde Dehydrogenase 2 (ALDH2) in the bioactivation of organic nitrates like isosorbide dinitrate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfisoxazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfisoxazole\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sulfisoxazole administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for propranolol in elderly patients with heart failure and the GRK5 Leu41 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for propranolol in elderly heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for levodopa in a patient with the low-activity COMT 'Met/Met' genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in vortioxetine users with the SLC6A4 s/s genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target therapeutic range for plasma digoxin in a patient with a low-function ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which hydroxychloroquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydroxychloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of hydroxychloroquine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vortioxetine in an adolescent with the SLC6A4 s/s genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for vortioxetine in adolescents based on SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of O-desmethylvenlafaxine in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for O-desmethylvenlafaxine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of nadolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to nadolol therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma olanzapine concentrations in a patient with a high-activity UGT1A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to apixaban clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma monomethyl fumarate based on a patient's HCAR2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypersensitivity reactions to sulfasalazine in individuals who are NAT2 slow acetylators?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe diarrhea with abemaciclib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for chloramphenicol in a neonate with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloramphenicol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Neonate-specific dosing guidelines for chloramphenicol in G6PD deficient infants, considering risks of both hemolysis and gray baby syndrome.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should methadone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for methadone based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of pleural effusion with dasatinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for probenecid in a patient with gout and G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"probenecid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for probenecid in G6PD deficient patients with gout.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for glasdegib in AML patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2R1 enzyme in the 25-hydroxylation of vitamin D?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Kir6.2 potassium channel (KCNJ11), a component of the sulfonylurea receptor, and how do its variants alter glimepiride's action?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the glucuronidation and detoxification of SN-38?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which probenecid causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"probenecid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of probenecid-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2D6 enzyme in the metabolism of ondansetron?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ondansetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Description of CYP2D6's metabolic pathway for ondansetron\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to clonazepam clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific capecitabine dosing recommendations for pediatric patients with DPYD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"capecitabine\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Pediatric dosing guidance for capecitabine in patients with DPYD deficiency\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for isoniazid in pediatric tuberculosis patients based on their NAT2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of developing type 2 diabetes in individuals with the KCNJ11 E23K variant, and how does it affect insulin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2 enzyme in the metabolism of anagrelide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for trastuzumab in HER2-positive breast cancer based on FCGR2A genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the proteasome beta-5 subunit (PSMB5), the primary target of bortezomib, and how do its mutations confer resistance?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2C9 in the primary metabolic pathway of nateglinide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the PDE5A enzyme, the target of sildenafil, and how might its variants alter drug binding and efficacy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A1 genotypes map to metformin hepatic uptake and efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ivermectin for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering sevoflurane to a patient with a pathogenic RYR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for sevoflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of argatroban for a patient with a specific variant affecting its hepatic metabolism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation with vemurafenib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity for a CYP2C9 poor metabolizer taking diclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for hepatotoxicity in CYP2C9 poor metabolizers using diclofenac.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ledipasvir for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for aceclofenac recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for aceclofenac based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chlorpropamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chlorpropamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with chlorpropamide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose adjustment for simvastatin based on ABCB1 transporter genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of flurbiprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in flurbiprofen's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of nabumetone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on nabumetone exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic effect measure for escitalopram based on OPRM1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of pindolol in patients with the ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of CNS adverse effects for a CYP2B6 poor metabolizer taking efavirenz?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"efavirenz\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf\", \"Content to Search\": \"Quantified risk data for CNS adverse effects in CYP2B6 poor metabolizers using efavirenz.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lovastatin in pediatric patients with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for lovastatin adjusted for SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target INR (International Normalized Ratio) range for a patient on warfarin, and how does CYP2C9 genotype affect the time to reach this range?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Data on time to stable INR based on CYP2C9 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neurotoxicity (encephalopathy) with ifosfamide in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should aripiprazole dosing be adjusted for a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mepacrine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mepacrine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with mepacrine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target cerebrospinal fluid concentrations of morphine in a patient with a high-activity ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of nilotinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced efficacy of inhaled ciclesonide in individuals with high-activity CES2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should oxcarbazepine be prescribed for a patient who is positive for the HLA-B*15:02 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Dosing recommendation or contraindication for oxcarbazepine in HLA-B*15:02 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of adverse effects to escitalopram for individuals with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for increased adverse effects of escitalopram in patients with the SLC6A4 S/S genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for capmatinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target INR range for a warfarin-treated patient based on their APOE genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP1A2 define a poor metabolizer in the context of ciprofloxacin therapy and its DDI potential?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2D6 in the metabolic clearance of chloroquine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for entrectinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of flurbiprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in flurbiprofen's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of alfentanil therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for alfentanil.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of farnesyl diphosphate synthase (FDPS) inhibition in the mechanism of action of pamidronate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of diazepam for a patient with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"norfloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of CYP2D6 in the bioactivation of tolterodine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which chloramphenicol causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloramphenicol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of chloramphenicol-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for pemigatinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma atorvastatin concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for atorvastatin in CYP2C9 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for mercaptopurine inactivation that is catalyzed by TPMT?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Biochemical reaction catalyzed by TPMT in the metabolism of mercaptopurine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for etoposide in a patient with a high-activity ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation with hydroxyzine in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should acebutolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for acebutolol based on ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of sulfapyridine in a patient with a NAT2 rapid acetylator genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should phentermine dosing be adjusted for a patient with a specific FTO gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 enzyme in the context of nadolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on nadolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should venlafaxine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for venlafaxine based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in atenolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma acebutolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for acebutolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which IFNL4 genotypes are linked to a poor response to peginterferon alfa-2b therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Genotype definitions (e.g., containing the ΔG allele) for the IFNL4 unfavorable response phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for citalopram in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to alfuzosin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SCNN1A genotypes correlate with amiloride response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ondansetron in a patient with a low-function ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C9 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for erythromycin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the cyclooxygenase-1 enzyme (PTGS1) and how do its variants alter aspirin's binding and inhibitory effect?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking methylene blue?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methylene blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with methylene blue use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended duloxetine dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for duloxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the BCR-ABL inhibitor bosutinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do PTGS1 genotypes correlate with the antiplatelet effect of low-dose aspirin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should alfentanil dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for alfentanil in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of duloxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's primary role in the metabolic pathway of duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the beta-1 adrenergic receptor (ADRB1) and how do its variants alter metoprolol's effects?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of rhabdomyolysis with trabectedin in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of tamsulosin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCG2 genotypes correlate with topotecan clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pindolol in elderly patients with heart failure and the GRK5 Leu41 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for pindolol in elderly heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should betaxolol dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for betaxolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correlate with clearance phenotypes for both artemether and lumefantrine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How is the IFNL3 genotype used to define the overall response phenotype for peginterferon/ribavirin combination therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Definition of response phenotypes for combination therapy based on IFNL3 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for bosutinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the biliary and renal excretion of topotecan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended aspirin dose for a G6PD deficient individual, particularly regarding high vs. low doses?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dose-specific recommendations for aspirin use (e.g., analgesic vs. antiplatelet doses) in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of excessive sedation in a CYP2C19 poor metabolizer taking doxepin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of sedation or other CNS effects in CYP2C19 poor metabolizers on doxepin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for citalopram in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CACNA1S gene in the mechanism of isoflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the CACNA1S gene function and its role in the pathophysiology of isoflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A5 enzyme in the metabolism of simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A5's role in simvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for maraviroc in patients with known CYP3A4 variants who are also on a strong CYP3A4 inducer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of nebivolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on nebivolol effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should desvenlafaxine dosing be adjusted for an individual with the SLC6A4 L/L genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for desvenlafaxine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C19 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A6/SLC22A8 genotypes correlate with meropenem clearance and neurotoxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for netilmicin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"netilmicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for netilmicin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of capmatinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of thioguanine for a patient who is a NUDT15 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dose adjustment protocol for thioguanine in NUDT15 intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for celecoxib in a patient with a CYP2D6 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose reduction of mercaptopurine for a TPMT poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Specific dose reduction (e.g., percentage) for mercaptopurine in TPMT poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should olaparib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should felodipine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended buprenorphine dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for buprenorphine in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of next-day somnolence with ramelteon in individuals with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma bendamustine concentrations in a CYP1A2 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering dibekacin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dibekacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for dibekacin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for desflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for desflurane in the context of RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of tedizolid's weak, reversible inhibition of Monoamine Oxidase A?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected plasma concentration of fluorouracil in a DPYD poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluorouracil\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Pharmacokinetic data comparing fluorouracil plasma concentrations between DPYD poor and normal metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for propranolol stratified by ADRB1 Ser49Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for omeprazole therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ciprofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pitavastatin concentrations in a CYP3A4 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pitavastatin in CYP3A4 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for indomethacin dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for indomethacin therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correspond to aprepitant metabolism and chemotherapy-induced nausea prevention phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pravastatin dose for a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pravastatin in CYP3A5 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for nebivolol in a patient with a CYP2D6 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which POLG1 genotypes are considered a contraindication for valproic acid therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism by which valproic acid toxicity is exacerbated in patients with POLG1 mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of acute phase reactions with zoledronic acid in individuals with specific FDPS variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define SLCO1B1 normal function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding function scores for the SLCO1B1 normal function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of central nervous system toxicity with high-dose loperamide abuse in individuals with ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should rivaroxaban dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the glucuronidation of pravastatin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma paroxetine concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for paroxetine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A4's role in rosuvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should venlafaxine dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for venlafaxine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for erlotinib in lung cancer patients who smoke, based on their CYP1A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered sufentanil response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on sufentanil response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of CNS side effects (e.g., dizziness) with propafenone in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for paroxetine in an adolescent with the SLC6A4 s/s genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for paroxetine in adolescents based on SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP2C9 poor metabolizers using pitavastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of vismodegib for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should metformin dosing be adjusted for a patient with a low-function OCT1 (SLC22A1) genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ziprasidone concentrations in a patient with combined CYP3A4 and CYP1A2 decreased function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carvedilol in patients with asthma and an ADRB2 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for carvedilol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CHRM3 genotypes correlate with ipratropium response phenotypes in COPD?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of prolonged hypoglycemia with gliclazide in patients with CYP2C9*2 or *3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the efflux of tamoxifen and its metabolites from cancer cells?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 ultrarapid metabolizer status affect the plasma concentration of trimipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pharmacokinetic data on trimipramine plasma concentrations in CYP2C19 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific atazanavir dosing recommendations for pediatric patients with a UGT1A1 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atazanavir\", \"Gene Name\": \"UGT1A1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf\", \"Content to Search\": \"Atazanavir dosing guidelines for pediatric patients with the UGT1A1 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of empagliflozin for a patient with a specific UGT2B7 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP3A4 in the metabolism of the thiazide-like diuretic indapamide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which aminosalicylic acid causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aminosalicylic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of aminosalicylic acid-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 enzyme in the context of nebivolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on nebivolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced virologic response to sofosbuvir-based regimens in individuals with high-activity ABCB1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nadolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nadolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of drug interactions with omeprazole in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to hydroxyurea for sickle cell disease in individuals with specific RRM1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should cytarabine (Ara-C) dosing be adjusted for a patient with a CDA (cytidine deaminase) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ciprofloxacin for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should methadone dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for methadone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with valsartan in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target intracellular concentrations of cladribine triphosphate in a patient with a high-activity DCK genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of meloxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on meloxicam exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of bisoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofural\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended milnacipran dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for milnacipran in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for larotrectinib in pediatric patients with NTRK fusion-positive tumors and known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for sotalol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should caspofungin dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking hydrocodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of hydrocodone in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for betaxolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding function scores for the SLCO1B1 intermediate function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma teriflunomide concentrations in a CYP2C8 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of headache and back pain with tadalafil in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for milnacipran in an adolescent with the SLC6A4 s/s genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for milnacipran in adolescents based on SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target absolute neutrophil count (ANC) for a G-CSF-treated patient based on their CSF3R genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolbutamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pitavastatin in pediatric patients with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for pitavastatin adjusted for ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"neomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should procarbazine dosing be adjusted for a patient with a specific MAO (Monoamine Oxidase) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma atorvastatin concentrations in an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for atorvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for venlafaxine based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2C9 in the metabolic pathway of leflunomide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pralsetinib in RET fusion-positive lung cancer patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bupropion dosing be adjusted for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended metoprolol dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for metoprolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of theophylline toxicity in individuals who are CYP1A2 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ribociclib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should carvedilol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for carvedilol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of vestibulotoxicity with amikacin in individuals with MT-RNR1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the NKCC2 cotransporter (encoded by SLC12A1) as the direct target of bumetanide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of naproxen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in naproxen's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cinchonism with quinine in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended efavirenz dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"efavirenz\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf\", \"Content to Search\": \"Dose adjustment protocol for efavirenz in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of B-cell depletion for a rituximab-treated patient based on their FCGR3A genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC47A1 genotypes correlate with trimethoprim-induced renal toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using venlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does the recommended dosing of peginterferon alfa-2a change for a patient with a favorable IFNL3 genotype (e.g., rs12979860 CC)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Dose adjustment protocol or clinical recommendation for peginterferon alfa-2a based on IFNL3 favorable response genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ibrutinib in CLL patients with known CYP3A4 variants who are also on a moderate CYP3A4 inhibitor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of adverse effects to levomilnacipran for individuals with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for increased adverse effects of levomilnacipran in patients with the SLC6A4 S/S genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC12A1 genotypes correlate with bumetanide response phenotypes in edema?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation and hepatotoxicity with ribociclib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended gabapentin dose for a patient with a low-function SLC22A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic monitoring strategy for a gentamicin-treated patient with a known MT-RNR1 risk variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OCT2 transporter (SLC22A2) in the renal elimination of dalfampridine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using sertraline.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"netilmicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should levomilnacipran dosing be adjusted for an individual with the SLC6A4 L/L genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for levomilnacipran based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of acetaminophen for a patient with a SULT1A1*2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of fluoxetine for a patient with the HTR2C -759C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of donepezil for a patient with a specific variant in the ACHE (acetylcholinesterase) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the metabolism of desvenlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in the metabolic pathway of desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mafenide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mafenide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with mafenide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CDA genotypes map to gemcitabine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for carvedilol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with morphine dose requirements for analgesia?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dose adjustment for esomeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esomeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidance for esomeprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is the dose of ribavirin adjusted based on a patient's IFNL3 genotype when used in combination with peginterferon?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Ribavirin dose adjustment protocol based on IFNL3 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of enzalutamide for a patient who is a CYP2C8 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with amoxicillin in infections caused by bacteria with altered PBP genes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to duloxetine for individuals with the HTR2A rs7997012 A allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered duloxetine efficacy in patients with the HTR2A rs7997012 A allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C19 diplotypes define a rapid metabolizer for the purpose of diazepam therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 gene product in the context of nadolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for nadolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for nabumetone use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for nabumetone in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma valsartan concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C9 diplotypes (*2, *3) correspond to poor antihypertensive response phenotypes for losartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for paroxetine in an elderly patient with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for paroxetine in elderly CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of non-response to escitalopram in OPRM1 G-allele carriers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C19 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the incidence of leukopenia in Asian patients with the NUDT15 risk allele when treated with mercaptopurine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Incidence rates of leukopenia in Asian populations with NUDT15 variants taking mercaptopurine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for axitinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of crizotinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the FTO gene in appetite regulation and its potential interaction with phentermine's mechanism of action?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to tolazamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolazamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after tolazamide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sertraline dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for sertraline in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfasalazine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfasalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sulfasalazine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myopathy with atorvastatin in individuals with reduced UGT1A1 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of quinidine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tamoxifen dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of labetalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the beta-2 adrenergic receptor and its interaction with labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pravastatin dose for an individual with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pravastatin in individuals with SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking atorvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 receptor in the mechanism of action of bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma propofol concentrations during anesthesia in a patient with a high-activity UGT1A9 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target 6-TGN metabolite levels for an azathioprine-treated patient based on their GSTP1 Ile105Val polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking high-dose aspirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with high-dose aspirin use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma methadone concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for methadone stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for escitalopram in adolescents with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for escitalopram in adolescent patients, adjusted for HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested platelet count monitoring thresholds for a linezolid-treated patient based on their genetic risk?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended simvastatin dose for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for simvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to selpercatinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma lovastatin concentrations in a CYP3A4 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for lovastatin in CYP3A4 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with gemfibrozil safety and efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OAT3 transporter in the active tubular secretion of sitagliptin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of promethazine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for dalfampridine in a patient with a high-function SLC22A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of propranolol in patients with the ADRB1 Arg389Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of romiplostim for a patient with a specific variant in the TPO-R (thrombopoietin receptor, MPL) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of seizures with meropenem in individuals with low-function OAT transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected level of 6-methylmercaptopurine (6-MMP) metabolites in a TPMT normal metabolizer taking thioguanine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Pharmacokinetic data on 6-MMP levels in TPMT normal metabolizers on thioguanine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for esmolol in patients with hypertension and a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for esmolol in hypertensive patients, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for diazepam in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of elevated transaminases for patients with a responsive CFTR genotype taking ivacaftor?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ivacaftor\", \"Gene Name\": \"CFTR\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf\", \"Content to Search\": \"Incidence rates or quantified risk of elevated transaminases in patients on ivacaftor therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the FLT3 inhibitor midostaurin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atorvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for atorvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should lorlatinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for omeprazole in pediatric GERD patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in esmolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of oxymorphone toxicity for a CYP2D6 ultrarapid metabolizer taking oxycodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk, incidence rate, or odds ratio for oxymorphone toxicity in CYP2D6 UMs using oxycodone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of mirtazapine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking desvenlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should morphine dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for morphine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nitrofural?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofural\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with nitrofural use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the alternative antibiotic recommendations for a patient with a life-threatening infection who has a high-risk MT-RNR1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esomeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions corresponding to the CYP2C19 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in diclofenac exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on diclofenac exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should guanfacine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of muscle-related side effects with pravastatin in individuals with reduced UGT1A1 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended metoprolol dose for an individual with the ADRA2C Ins/Del polymorphism associated with decreased response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for metoprolol based on ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the context of citalopram therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for venlafaxine in an adolescent with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for venlafaxine in adolescents based on HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for ribostamycin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribostamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for ribostamycin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ganciclovir concentrations in a patient with a high-function OAT1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for oxycodone in pediatric patients with an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for oxycodone in pediatric patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tacrolimus in pediatric liver transplant recipients based on their ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bradycardia upon first dose of fingolimod in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for modafinil in patients with known CYP3A4 variants who are also taking oral contraceptives?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma amlodipine concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to mafenide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mafenide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after mafenide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for tepotinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of adverse effects to desvenlafaxine for individuals with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for increased adverse effects of desvenlafaxine in patients with the SLC6A4 S/S genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for dabrafenib in a cancer patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dabrafenib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for dabrafenib in G6PD deficient cancer patients, considering the specific indication (e.g., melanoma).\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for ibuprofen in a TPMT intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested level of DNA cross-linking in tumor cells for a mitomycin C-treated patient based on their NQO1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvoxamine dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvoxamine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma aripiprazole concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose adjustment for tacrolimus based on ABCB1 transporter genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with tropisetron in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the GST family of enzymes in the detoxification of azathioprine metabolites?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target time above MIC for a meropenem-treated patient based on their OAT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ciprofloxacin in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ciprofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for ciprofloxacin in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering methoxyflurane to a patient with a pathogenic CACNA1S variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for methoxyflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluoxetine dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol or alternative medication recommendation for fluoxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of HMGCR in the mechanism of action of pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of HMGCR as the pharmacological target of pravastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to nitrofural?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofural\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after nitrofural administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for avapritinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypotension with azilsartan in patients with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes map to dabigatran exposure and efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the RYR1 gene in the mechanism of desflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the RYR1 gene function and its role in the pathophysiology of desflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for lovastatin in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carfilzomib in multiple myeloma patients with a history of bortezomib resistance due to a PSMB5 mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A4 genotypes map to idelalisib clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes map to ivermectin safety and efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is mafenide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mafenide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for mafenide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bone marrow suppression with albendazole in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 genotypes are associated with enhanced beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to methadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and methadone's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to the severity of drug-drug interactions caused by ketoconazole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of thrombocytopenia with long-term linezolid use in individuals with variants in mitochondrial protein synthesis genes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma alfuzosin concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for eplerenone in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do AGTR1 genotypes correlate with antihypertensive response phenotypes to losartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for esmolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the proposed mechanism for HLA-B*58:01-mediated allopurinol-induced SCARs?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"allopurinol\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf\", \"Content to Search\": \"Description of the immunological mechanism involving HLA-B*58:01 and allopurinol\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 intermediate metabolizer for nateglinide therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of sirolimus (the active metabolite of temsirolimus) in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking moxifloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"moxifloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with moxifloxacin use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for lurasidone involving the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the VKORC1 enzyme in the vitamin K cycle, and how does warfarin inhibit it?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"VKORC1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Mechanism of action of warfarin on the VKORC1 enzyme within the vitamin K cycle\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of pneumonitis with pembrolizumab in individuals with specific PDCD1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in piroxicam exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on piroxicam exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to escitalopram in a patient with the HTR2A rs7997012 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for escitalopram stratified by HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nausea with duloxetine in individuals with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ITGA4 genotypes correlate with natalizumab efficacy phenotypes in multiple sclerosis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomethadone in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for levomethadone adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as blood pressure changes, for metoprolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of tacrolimus for a CYP3A5 expresser (intermediate metabolizer)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tacrolimus\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf\", \"Content to Search\": \"Recommended tacrolimus starting dose for CYP3A5 intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the likelihood of achieving SVR with a peginterferon/ribavirin regimen in a patient with a favorable IFNL3 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Quantified SVR rates for combination therapy with ribavirin in patients with favorable IFNL3 genotypes\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ruxolitinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for celecoxib use in pediatric patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for celecoxib in pediatric CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does the HLA-A*31:01 allele affect the pharmacokinetics of oxcarbazepine or its active metabolite?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Pharmacokinetic data for oxcarbazepine in relation to HLA-A*31:01 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should topiramate dosing be adjusted for a patient with a CA2 (Carbonic Anhydrase II) deficiency?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in paroxetine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for acebutolol in patients with heart failure and a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for acebutolol in heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A5 enzyme in the metabolism of atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A5's role in atorvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of diclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in diclofenac's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do nucleoside transporter genotypes correlate with fludarabine efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of oxycodone therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for oxycodone's active metabolite, oxymorphone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma sertraline concentrations in a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges for sertraline in CYP2C19 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to morphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and morphine's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vortioxetine dosing be adjusted for an individual with the SLC6A4 l/l genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vortioxetine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vilazodone dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vilazodone in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of duloxetine in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for duloxetine in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vitamin D (cholecalciferol) dosing be adjusted for a patient with a specific variant in the CYP2R1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 receptor in the mechanism of action of betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for enzalutamide in prostate cancer patients with a known CYP2C8*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does IFNL3 genotype influence the risk of ribavirin-induced anemia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Pharmacodynamic or safety data linking IFNL3 genotype to the incidence of ribavirin-induced anemia\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should betaxolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for betaxolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to eplerenone clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended rosuvastatin dose for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for rosuvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for empagliflozin in heart failure patients based on their UGT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should morphine dosing be adjusted for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected plasma concentration of amitriptyline in a CYP2C19 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pharmacokinetic data comparing amitriptyline plasma concentrations between CYP2C19 poor and normal metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested urinary sodium excretion target for a furosemide-treated patient based on their SLC12A1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing drug-resistant epilepsy with phenytoin in individuals with high-activity ABCB1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 intermediate metabolizer for vincristine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ponatinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 variants and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do hepatic function-related genotypes correlate with argatroban clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of losartan's active metabolite, E-3174, in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing severe depression with interferon alfa in individuals with specific STAT1 gain-of-function mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does the HLA-B*58:01 allele affect the pharmacokinetics of allopurinol or its active metabolite, oxypurinol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"allopurinol\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf\", \"Content to Search\": \"Pharmacokinetic data for allopurinol or oxypurinol in relation to HLA-B*58:01 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of natalizumab for a patient with a specific variant in the ITGA4 (integrin alpha 4) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using paroxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for zolpidem therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific guidelines for using oxcarbazepine in pediatric patients with the HLA-A*31:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Pediatric dosing or clinical guidance for oxcarbazepine in HLA-A*31:01 positive children\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for labetalol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP2C9's role in atorvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of PDE5A inhibition for a sildenafil-treated patient based on their genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myelosuppression with ganciclovir in individuals with low-function OAT1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of drug interactions (e.g., with warfarin) when cimetidine is used by a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of seizures with bupropion in patients with reduced CYP2B6 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering desflurane to a patient with a pathogenic CACNA1S variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for desflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with GRK4 variants taking carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse effects with propranolol in patients carrying TPMT deficiency alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nadolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nadolol in patients of African ancestry, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pitavastatin concentrations in an individual with SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pitavastatin in individuals with SLCO1B1 intermediate function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for isoflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for isoflurane in the context of CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering streptomycin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"streptomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for streptomycin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of buprenorphine for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for acebutolol in elderly patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for acebutolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is chloramphenicol contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloramphenicol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for chloramphenicol in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to fluvoxamine in a patient with the HTR2A rs7997012 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for fluvoxamine stratified by HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Carboxylesterase 2 (CES2) in the bioactivation of ciclesonide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HTR2A variants are associated with altered fluoxetine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of HTR2A variants and their corresponding impact on fluoxetine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should insulin dosing be adjusted for patients with the KCNJ11 E23K polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking methadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for methadone in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to tobramycin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tobramycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with tobramycin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to ripretinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking fluvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of pulmonary toxicity with long-term nitrofurantoin use in individuals with genetic predispositions to lung fibrosis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to nalidixic acid?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nalidixic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after nalidixic acid administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for O-desmethylvenlafaxine in a patient with a high-activity ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for ifosfamide therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in venlafaxine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 gene product in the context of pindolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for pindolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the clinical recommendation for carbamazepine use in a patient who tests positive for the HLA-B*15:02 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Dosing recommendation or contraindication for carbamazepine in HLA-B*15:02 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ondansetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should cimetidine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for carmustine in a patient with a high-activity GSTP1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for metoprolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for metoprolol in patients of African ancestry, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of thromboembolic events with tamoxifen in patients with CYP2C9*2 or *3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP2C9 define a poor metabolizer in the context of fluconazole therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the MATE1 transporter (encoded by SLC47A1) in the final step of metformin elimination from the body?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma clozapine concentrations in a patient who is a CYP1A2 rapid metabolizer and a heavy caffeine user?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to indapamide clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carvedilol in patients with heart failure and a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for carvedilol in heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP3A4 diplotypes define an intermediate metabolizer for the purposes of verapamil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pravastatin concentrations in an individual with SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pravastatin in individuals with SLCO1B1 intermediate function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pravastatin dose for an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pravastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin k\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma aliskiren concentrations in a patient with a high-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FCGR3A genotypes correlate with rituximab efficacy phenotypes in autoimmune diseases and cancer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific amitriptyline dosing recommendations for pediatric patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pediatric dosing guidance for amitriptyline in CYP2C19 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma mycophenolic acid (MPA) in a patient with a high-activity UGT1A9 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for duloxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydroxychloroquine in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydroxychloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for hydroxychloroquine in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of extrapyramidal symptoms with risperidone in a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered buprenorphine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on buprenorphine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using sertraline.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correlate with the conversion of albendazole to its active metabolite?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correlate with the severity of drug-drug interactions caused by diltiazem?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ibrutinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with cetirizine efficacy and side effect phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HLA-B gene in the immune system?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Basic function and role of the HLA-B gene\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for labetalol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sodium nitrite?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sodium nitrite\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sodium nitrite use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of duloxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in the metabolic pathway of duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma fentanyl concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for fentanyl stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of metoprolol in patients with the ADRB1 Arg389Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for dapsone in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dapsone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for dapsone in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in sertraline metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended hydromorphone dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for hydromorphone in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ledipasvir based on a patient's ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter in the hepatic uptake of montelukast?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for mepacrine in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mepacrine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for mepacrine in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for atorvastatin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should mycophenolate mofetil (MMF) dosing be adjusted for a patient with a specific UGT1A9 promoter polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HMGCR variants are associated with altered statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Definitions of HMGCR variants or genotypes associated with altered statin efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for escitalopram in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer for terbinafine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 polymorphism affect the first-pass metabolism of omeprazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"omeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Description of CYP2C19's role in omeprazole's mechanism and metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of prolonged sedation with midazolam in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma concentrations of selegiline's amphetamine metabolites in a CYP2B6 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Monoamine Oxidase enzymes in the metabolism of procarbazine and its interaction with sympathomimetic amines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the mitochondrial ribosome and how do MT-RNR1 variants increase its affinity for amikacin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic strategy for a patient whose tumor has an NRAS mutation, regarding panitumumab therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypoglycemia with glipizide in patients with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of amiodarone-induced liver injury in patients with CYP2C8 poor metabolizer status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for enflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for enflurane in the context of RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bisoprolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for bisoprolol based on ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target intragastric pH for an omeprazole-treated patient based on their ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the correspondence between the HLA-B*15:02 genotype and the phenotype of high risk for fosphenytoin-induced SJS/TEN?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Definition of the high-risk phenotype associated with the HLA-B*15:02 allele for fosphenytoin use\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCG2 genotypes correlate with allopurinol response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sulfasalazine in a patient with rheumatoid arthritis and G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfasalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for sulfasalazine in G6PD deficient patients with rheumatoid arthritis.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe gastrointestinal side effects with rivastigmine in patients with BCHE deficiency?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pitavastatin in pediatric patients with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for pitavastatin adjusted for SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma cytarabine concentrations in a patient with a high-activity CDA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the fosphenytoin dosing recommendation for a neonate with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for fosphenytoin in neonates with CYP2C9 poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vortioxetine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for vortioxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloramphenicol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for continuous intravenous nitroglycerin in ICU patients with a known ALDH2 deficiency?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FTO genotypes correlate with phentermine efficacy phenotypes for weight management?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A6 genotypes map to salicylate clearance phenotypes following bismuth subsalicylate administration?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose adjustment for thioguanine in a patient who is a TPMT intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dose reduction protocol for thioguanine in TPMT intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for propranolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ranitidine for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of doxepin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Role of CYP2D6 in the metabolic clearance of doxepin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of repaglinide for a patient with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of acyclovir for a patient with a specific organic anion transporter (OAT1/SLC22A6) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for apixaban in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the P-glycoprotein (ABCB1) in the distribution and clearance of ondansetron?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of levomilnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in the metabolic pathway of levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydromorphone in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for hydromorphone in cancer patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for quetiapine in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lovastatin in pediatric patients with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for lovastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for plazomicin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"plazomicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for plazomicin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for a dasatinib-treated patient based on their ABCG2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 intermediate metabolizer for bupropion therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of levomethadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in levomethadone metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with GRK4 variants taking atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lovastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for lovastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of metronidazole for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific guidelines for using peginterferon alfa-2b in patients of Asian descent based on their IFNL4 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Treatment recommendations for peginterferon alfa-2b in Asian patients stratified by IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for esmolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target blood pressure limit for a pseudoephedrine-treated patient based on their MAOA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of ribonucleotide reductase, the target of hydroxyurea, and how do its variants alter drug sensitivity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rosuvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for rosuvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking sufentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using sufentanil.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sufentanil in children with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for sufentanil in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define ABCG2 normal function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the ABCG2 normal function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is gliclazide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gliclazide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for gliclazide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma naltrexone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for naltrexone stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe myelosuppression with lomustine in patients with a methylated MGMT promoter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking aminosalicylic acid?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aminosalicylic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with aminosalicylic acid use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvastatin in pediatric patients with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for fluvastatin adjusted for SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of sofosbuvir for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of tamoxifen for a patient with a SULT1A1*2/*2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with pramipexole in individuals with SLC22A2 variants that reduce renal clearance?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in lumiracoxib exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on lumiracoxib exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should teriflunomide dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in propranolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking naproxen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using naproxen.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 gene product in the context of acebutolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cognitive effects and intracranial hemorrhage with avapritinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for initiating oxcarbazepine in a pregnant patient who is an HLA-B*15:02 carrier?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Guidance for oxcarbazepine use during pregnancy in HLA-B*15:02 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors correlate with cromolyn efficacy phenotypes in asthma?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered opioid response or dose requirements?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on opioid response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for lumiracoxib use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for lumiracoxib in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose adjustment for clomipramine in a patient who is a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for clomipramine in CYP2C19 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of fentanyl?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in fentanyl metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of warfarin for a patient with a Factor V Leiden (F5) mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended venlafaxine dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for venlafaxine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for abacavir in a patient who is positive for the HLA-B*57:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"abacavir\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf\", \"Content to Search\": \"Clinical recommendation and dosing guidance for abacavir in HLA-B*57:01 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation with glasdegib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of sotalol in patients with high-activity GRK4 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to modafinil metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with remdesivir safety and efficacy phenotypes in COVID-19?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the efflux and bioavailability of dasatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target aPTT for an argatroban-treated patient with HIT based on their genotype for a relevant metabolizing enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of sotalol in patients with the ADRB2 Gln27Glu polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of simeprevir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic trough concentration for tacrolimus in a patient homozygous for the POR*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nadolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nadolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of sufentanil for a patient identified as a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GLP-1 receptor, the target of liraglutide, and how do its variants alter drug signaling?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the carbamazepine dosing recommendation for a child of Southeast Asian ancestry who is positive for HLA-B*15:02?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Pediatric dosing recommendations for carbamazepine in HLA-B*15:02 positive children, particularly of specific ancestries\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C8 genotypes map to brigatinib metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma alprazolam concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of adverse effects to duloxetine for individuals with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for increased adverse effects of duloxetine in patients with the SLC6A4 S/S genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vardenafil in elderly patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of excessive sedation with promethazine in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2 enzyme in the metabolic clearance of duloxetine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the context of levomilnacipran therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for simvastatin in pediatric patients with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for simvastatin adjusted for SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of indomethacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in indomethacin's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for esmolol in elderly patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for esmolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ALDH2 genotypes define response phenotypes to nitroglycerin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP2C9 poor metabolizers using pravastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dofetilide for a patient with a specific KCNH2 (hERG) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected area under the curve (AUC) for esomeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esomeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on esomeprazole exposure in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the M3 muscarinic receptor (CHRM3), the target of ipratropium, and how do its variants alter drug affinity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of selpercatinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vilazodone in an adolescent with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for vilazodone in adolescents based on HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2C19 in the metabolism of trimipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Function of CYP2C19 in the metabolic pathway of trimipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the ACE gene in determining individual response to lisinopril?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in milnacipran metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Brain-Derived Neurotrophic Factor (BDNF) and its potential role in the mechanism of action of fluoxetine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced bronchodilation with ipratropium in individuals with specific CHRM3 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vemurafenib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to gentamicin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gentamicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with gentamicin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C8 genotypes correlate with montelukast clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of failing to achieve adequate 25-hydroxyvitamin D levels with standard vitamin D supplementation in individuals with low-function CYP2R1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cetirizine for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with aceclofenac in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using aceclofenac.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OCT1 transporter (encoded by SLC22A1) in the therapeutic action of metformin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of pseudoephedrine for a patient with a specific MAOA variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT2B7 enzyme in the metabolism and elimination of zidovudine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to netilmicin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"netilmicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with netilmicin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal adverse effects with MMF in patients with low-activity UGT1A9 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of glimepiride for a patient with a specific variant in the KCNJ11 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should loratadine dosing be adjusted for a patient with low-function ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe hand-foot skin reaction and hepatotoxicity with regorafenib in individuals with low-activity UGT1A9 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolic pathway of ranitidine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of trazodone to its active metabolite, m-CPP?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of propofol infusion syndrome in individuals with low-activity UGT1A9 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for methadone in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for methadone adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma naltrexone concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for naltrexone stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OCT2 transporter (SLC22A2) in the renal secretion of pramipexole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for sevoflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for sevoflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of akathisia in aripiprazole-treated patients who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the bioavailability of ledipasvir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse CNS effects with praziquantel in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for desflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for desflurane in the context of CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for duloxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nadolol stratified by ADRB1 Ser49Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma diphenhydramine concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with simeprevir-induced photosensitivity reactions?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pharmacodynamic data (LDL-C reduction) for atorvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended simvastatin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for simvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for sevoflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for sevoflurane in patients with RYR1-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of flecainide for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for 4-hydroxyatomoxetine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target trough plasma concentration for voriconazole to ensure efficacy and minimize toxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"voriconazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values or target trough concentration range for voriconazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A4 enzyme in the glucuronidation of olanzapine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for paclitaxel in a patient with a specific ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended phenytoin dosing adjustment for a pediatric patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for phenytoin based on CYP2C9 poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correlate with dutasteride clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 variants and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with GRK4 variants taking bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of rifampin for a patient who is a SLCO1B1 poor transporter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 genotypes are associated with enhanced beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of lisdexamfetamine's enzymatic conversion in the blood?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tramadol dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for tramadol based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma clozapine concentrations in a CYP1A2 ultrarapid metabolizer (e.g., a heavy smoker)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with lornoxicam in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using lornoxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for oral midazolam in pediatric sedation based on their CYP3A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of orlistat for a patient with a specific variant in the pancreatic lipase (PNLIP) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of propranolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on propranolol effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of rhabdomyolysis for lovastatin users with decreased CYP3A4 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A1 genotypes correlate with pravastatin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of haloperidol therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with rivaroxaban exposure phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected impact of the CYP2B6 ultrarapid metabolizer phenotype on (R)-methadone plasma concentrations?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacokinetic data on (R)-methadone plasma levels in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target concentration of des-ciclesonide (active metabolite) in the lungs of a patient based on their CES2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of hydrocodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in converting hydrocodone to its active metabolite, hydromorphone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma cycloguanil (active metabolite) concentrations in a CYP2C19 normal metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma morphine concentrations (from codeine) in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for morphine (active metabolite of codeine) stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bradycardia for a CYP2D6 poor metabolizer taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for bradycardia or other adverse effects in CYP2D6 poor metabolizers using metoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding for a warfarin patient who is a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Quantified risk data for bleeding events in CYP2C9 intermediate metabolizers on warfarin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the ABCG2 decreased function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 receptor in the mechanism of action of atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of ataxia and cognitive impairment with clonazepam in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for palbociclib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvastatin dose for an individual with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma olaparib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should escitalopram dosing be adjusted for an individual with the SLC6A4 L/L genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for escitalopram based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific doxepin dosing recommendations for patients with comorbid anxiety who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing guidance for doxepin in patients with anxiety and CYP2C19 poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma lenvatinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with levofloxacin in infections caused by bacteria with gyrA mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for ribociclib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target platelet reactivity unit (PRU) for a clopidogrel-treated patient based on their PON1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should acebutolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for acebutolol based on ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking ibuprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using ibuprofen.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of escitalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in the metabolic pathway of escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of guaifenesin for a patient with a genetic variant affecting its unknown metabolic pathway?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of mepolizumab for a patient with a specific variant in the IL5RA (interleukin-5 receptor alpha) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of mineralocorticoid excess with abiraterone in individuals with low-activity SULT2A1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sotalol dose for an individual with the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for sotalol based on ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for canagliflozin in a patient with a high-activity UGT1A9 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sulfasalazine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfasalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sulfasalazine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of atomoxetine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for vilazodone based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of amitriptyline for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Recommended starting dose and titration protocol for amitriptyline in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of therapeutic failure for a CYP2C19 ultrarapid metabolizer on a standard dose of imipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of non-response in CYP2C19 ultrarapid metabolizers taking imipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the hydroxylation of imipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Role of CYP2D6 in the metabolic clearance of imipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A1 genotypes correlate with enasidenib-induced hyperbilirubinemia?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which furazolidone causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"furazolidone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of furazolidone-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the VKORC1 -1639G>A genotype affect the pharmacodynamics of warfarin, specifically the dose-response relationship?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"VKORC1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Pharmacodynamic data describing the effect of VKORC1 genotype on warfarin dose-response\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dose adjustment for omeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"omeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidance for omeprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for vandetanib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for sorafenib in a patient with a high-activity UGT1A9 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2C19 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for desvenlafaxine in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of asenapine for a patient with the UGT1A4*3/*3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What combination of CYP2D6 and CYP3A4 diplotypes would predict the highest galantamine exposure?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FXR genotypes correlate with the lipid-lowering response to cholestyramine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of morphine in a CYP2D6 poor metabolizer after a standard dose of codeine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration data for morphine (the active metabolite of codeine) in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nalidixic acid in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nalidixic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for nalidixic acid in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor hematopoietic recovery with G-CSF in individuals with low-function CSF3R variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for promethazine in pediatric patients with a CYP2D6 gene duplication?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MTHFR genotypes correlate with pemetrexed efficacy and toxicity phenotypes in non-small cell lung cancer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bradycardia and visual disorders with crizotinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is glimepiride contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glimepiride\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for glimepiride in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vincristine in pediatric leukemia patients based on their CYP3A5 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma pioglitazone concentrations in a CYP2C8 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of nirmatrelvir/ritonavir (Paxlovid) for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glipizide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glipizide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with glipizide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma levomethadone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for levomethadone stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to phenazopyridine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenazopyridine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after phenazopyridine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma terbinafine concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for fingolimod-phosphate (active metabolite) in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should diltiazem dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tramadol in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for tramadol adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to norfloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"norfloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after norfloxacin administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for loperamide in a patient with a low-function ABCB1 genotype to avoid cardiac toxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vilazodone in an elderly patient with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for vilazodone in elderly CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of major bleeding events with rivaroxaban in patients with specific ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended rosuvastatin dose for an individual with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for rosuvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of cytidine deaminase (CDA) in the inactivation of gemcitabine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking indomethacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using indomethacin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for neomycin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"neomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for neomycin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CFTR genotypes are considered responsive to ivacaftor therapy according to the CPIC guideline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ivacaftor\", \"Gene Name\": \"CFTR\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf\", \"Content to Search\": \"List of CFTR genotypes for which ivacaftor therapy is recommended.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with colchicine clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of extrapyramidal symptoms with haloperidol in CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of UGT1A9 in the metabolic clearance of the SGLT2 inhibitor canagliflozin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rosuvastatin in pediatric patients with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for rosuvastatin adjusted for SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of letrozole for a patient who is a CYP2A6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of metformin therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of eszopiclone for a patient identified as a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should misoprostol dosing be adjusted for a patient with a specific prostaglandin receptor (PTGER3) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pravastatin dose for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pravastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for azilsartan in a patient with a CYP2C9 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of caffeine's inhibition of the CYP1A2 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiotoxicity with trastuzumab in individuals with specific FCGR2A variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response for tiotropium in COPD based on a patient's CHRM3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to nirmatrelvir clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for fentanyl in a patient with a specific ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 variants and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended desvenlafaxine dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for desvenlafaxine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should acebutolol dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for acebutolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for theophylline in pediatric asthma patients based on their CYP1A2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking alfentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using alfentanil.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of lumiracoxib for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for lumiracoxib in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A4 poor metabolizers using rosuvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of rifampin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for flurbiprofen use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for flurbiprofen in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma milnacipran concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for milnacipran in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should levofloxacin dosing be adjusted for a patient with a specific variant in a DNA gyrase (gyrA) or topoisomerase IV (parC) gene of the infecting bacteria?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the RYR1 gene in the mechanism of succinylcholine-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the RYR1 gene function and its role in the pathophysiology of succinylcholine-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors correlate with linezolid-induced hematologic toxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the MurA enzyme in bacterial cell wall synthesis and how do its genetic alterations confer resistance to fosfomycin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of weight gain with fluoxetine in individuals with the HTR2C -759T allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma trazodone concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in individuals with HMGCR variants taking atorvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2E1 genotypes map to theophylline clearance phenotypes, especially in smokers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of central nervous system side effects with oxycodone in individuals with low-function ABCB1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for alprazolam in elderly patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with tenoxicam in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using tenoxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of myelosuppression with methotrexate in individuals homozygous for the MTHFR C677T variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should propofol dosing be adjusted for a patient with a UGT1A9 promoter polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for nortriptyline clearance involving the CYP2D6 enzyme?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Role of CYP2D6-mediated hydroxylation in nortriptyline metabolism\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with cladribine in individuals with low-activity DCK variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tropisetron dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A6 genotypes map to probenecid efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of ramiprilat in a patient with the ACE II genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for naproxen in a patient with a CYP2C9 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of flurbiprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on flurbiprofen exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of naproxen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in naproxen's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for remifentanil in pediatric patients with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for remifentanil adjusted for COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is nitrofurantoin contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofurantoin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for nitrofurantoin in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors correlate with sucralfate efficacy phenotypes for duodenal ulcers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for clindamycin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vortioxetine in an adolescent with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for vortioxetine in adolescents based on HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking tramadol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for tramadol in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nitrate tolerance with isosorbide dinitrate in individuals with low-activity ALDH2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes correspond to a CYP3A5 non-expresser (poor metabolizer) phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tacrolimus\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypertensive crisis with pseudoephedrine in individuals taking an MAOI who also have a specific MAOA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma osimertinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma abiraterone concentrations based on SULT2A1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperprolactinemia with risperidone in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should benralizumab dosing be adjusted for a patient with a specific variant in the IL5RA gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dabrafenib contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dabrafenib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for dabrafenib in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma fluvastatin concentrations in an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vilazodone dosing be adjusted for an individual with the SLC6A4 l/l genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vilazodone based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do BCHE genotypes correspond to rivastigmine hydrolysis and clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of flurbiprofen for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for flurbiprofen in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pravastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pravastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered methadone response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on methadone response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for quinine for malaria treatment in a G6PD deficient child?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"quinine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for quinine in G6PD deficient children for malaria treatment.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of failed therapy for a CYP2C19 ultrarapid metabolizer taking a standard dose of citalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for lack of efficacy in CYP2C19 ultrarapid metabolizers using citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atorvastatin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for atorvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for sotalol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for metformin in a patient with a high-function OCT1 transporter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended tacrolimus dosing for a pediatric kidney transplant recipient who is a CYP3A5 expresser?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tacrolimus\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf\", \"Content to Search\": \"Pediatric dosing recommendations for tacrolimus in CYP3A5 expressers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for allopurinol in a patient who tests positive for the HLA-B*58:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"allopurinol\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf\", \"Content to Search\": \"Clinical recommendation and dosing guidance for allopurinol in HLA-B*58:01 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gynecomastia with dutasteride in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for fluticasone therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific desipramine dosing guidelines for geriatric patients who are CYP2D6 intermediate metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Geriatric dosing recommendations for desipramine in CYP2D6 intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on heart failure outcomes with metoprolol in patients with the GRK5 Leu41 variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma tadalafil concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pantoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions corresponding to the CYP2C19 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for propranolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HMGCR variants are associated with altered statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Definitions of HMGCR variants or genotypes associated with altered statin efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tedizolid dosing be adjusted for a patient with a specific MAOA uVNTR polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with montelukast exposure and efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What VKORC1 genotypes correspond to the 'high sensitivity' phenotype for warfarin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"VKORC1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Genotype definitions for the high sensitivity warfarin phenotype related to VKORC1\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of fluvoxamine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's primary role in the metabolic pathway of fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC22A16 transporter in the uptake of doxorubicin into cells?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What IFNL3 genotype is considered to predict an unfavorable response to peginterferon alfa-2b?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Genotype definitions (e.g., rs12979860 CT or TT) for the IFNL3 unfavorable response phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypercalcemia with calcium carbonate supplements in individuals with inactivating mutations in the CASR gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for clarithromycin in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended azathioprine dosing for a pediatric patient with acute lymphoblastic leukemia (ALL) who is a NUDT15 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Pediatric dosing guidance for azathioprine in ALL patients with NUDT15 intermediate metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of mast cell degranulation inhibition for a cromolyn-treated patient based on their genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific clopidogrel dosing recommendations for pediatric patients with a CYP2C19 loss-of-function allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clopidogrel\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidance for clopidogrel based on CYP2C19 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of levomilnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of SLC6A4's role as the serotonin transporter, a primary target of levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for selpercatinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target therapeutic range for 6-thioguanine nucleotide (6-TGN) concentrations when treating inflammatory bowel disease with azathioprine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Therapeutic window or target concentration range for 6-TGN metabolites\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of zafirlukast for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered sertraline response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definitions of HTR2A genotypes and their association with sertraline efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 poor metabolizer for colchicine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fentanyl in children with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fentanyl in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 variants and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for solifenacin in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for endoxifen in a patient with a specific ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for milnacipran based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of propranolol in patients with the ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of endoxifen in a patient with a specific SULT1A1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the erythropoietin receptor (EPOR) in erythropoiesis and how do its variants alter response to EPO therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma torsemide concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A1 genotypes map to atorvastatin metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for isoflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for isoflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in individuals with HMGCR variants taking fluvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sirolimus in pediatric transplant recipients based on their CYP3A5 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nebivolol dose for an individual with the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nebivolol based on ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should carfilzomib dosing be adjusted for a patient with a specific variant in a proteasome subunit gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing adjustment for atazanavir in a patient with a UGT1A1 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atazanavir\", \"Gene Name\": \"UGT1A1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf\", \"Content to Search\": \"Dosing adjustment protocol or alternative therapy recommendation for atazanavir in UGT1A1 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the ACE gene in determining individual response to benazepril?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for simvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for simvastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperammonemic encephalopathy with valproic acid in individuals with low-activity UGT2B7 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2D6 enzyme contribute to the conversion of risperidone to its active metabolite?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HMGCR variants are associated with altered statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Definitions of HMGCR variants or genotypes associated with altered statin efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'high-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for tenoxicam use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for tenoxicam in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking buprenorphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for buprenorphine in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should milnacipran dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for milnacipran based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of piroxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on piroxicam exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for cefepime in elderly patients with renal impairment and a genotype predisposing to CNS toxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking meloxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using meloxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target LDL reduction for a cholestyramine-treated patient based on their FXR genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sertraline in an adolescent with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for sertraline in adolescents based on HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which nitrofurantoin causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofurantoin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of nitrofurantoin-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for using toluidine blue as a diagnostic dye in a G6PD deficient patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"toluidine blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for using toluidine blue as a dye in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 gene product in the context of esmolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR).\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with fluconazole in individuals with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for aminosalicylic acid in a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aminosalicylic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for aminosalicylic acid in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to nivolumab in patients whose tumors have low PD-L1 expression, and is this associated with germline CD274 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should azithromycin dosing be adjusted for a patient with a KCNH2 (hERG) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the Kir6.2 potassium channel (encoded by KCNJ11) in insulin secretion from pancreatic beta-cells?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should albendazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of rhabdomyolysis with sonidegib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of venlafaxine for a patient with an ABCB1 low-function haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of nabumetone for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for nabumetone in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing drug-induced lupus erythematosus with hydralazine in NAT2 slow acetylators?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should trimethoprim dosing be adjusted for a patient with a low-function MATE1 (SLC47A1) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should hydromorphone dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for hydromorphone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pharmacodynamic data (LDL-C reduction) for pravastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma O-desmethyltramadol concentrations (from tramadol) in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for O-desmethyltramadol (active metabolite of tramadol) stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer for aripiprazole therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for simvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for simvastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested QTc interval limit for an azithromycin-treated patient based on their KCNH2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to alfentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and alfentanil's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of toxicity in a CYP2C19 poor metabolizer taking trimipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of toxicity in CYP2C19 poor metabolizers on trimipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered desvenlafaxine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of SLC6A4 variants and their corresponding impact on desvenlafaxine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of sufentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in sufentanil metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ponatinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should atorvastatin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for altretamine in a patient with a CYP1A2 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which DPYD diplotypes define a normal metabolizer for the purpose of atorvastatin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sucralfate in pediatric patients with genetic renal disorders?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the mechanism of action of venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for venlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the 5-alpha reductase type 2 enzyme (SRD5A2) and how do its variants alter finasteride binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended metoprolol dose for an individual with a GRK4 variant associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for metoprolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperbilirubinemia with rifampin in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of treatment failure for VRE (Vancomycin-Resistant Enterococci) infections based on the specific van genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A6 genotypes map to acyclovir renal secretion phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for indomethacin use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for indomethacin in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rosuvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for rosuvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nebivolol dose for an individual with a GRK4 variant associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nebivolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lenalidomide in patients with del(5q) MDS based on their CRBN expression level?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which HLA-B allele is most strongly associated with phenytoin-induced severe cutaneous adverse reactions (SCARs)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Specific HLA-B allele linked to high risk of SCARs with phenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the G-CSF receptor (CSF3R) in mediating the effects of filgrastim on neutrophil production?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 polymorphism affect the first-pass metabolism of dexlansoprazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dexlansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Description of CYP2C19's role in dexlansoprazole's mechanism and metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of sedation and weight gain with mirtazapine in CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A4 enzyme in the metabolism of idelalisib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for flecainide in pediatric patients with supraventricular tachycardia and a CYP2D6 gene duplication?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for everolimus in transplant rejection prophylaxis based on a patient's CYP3A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing progressive multifocal leukoencephalopathy (PML) with natalizumab based on a patient's host genetic factors?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for carvedilol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of ibuprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in ibuprofen's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the clinical implication of testing positive for the HLA-A*31:01 allele before starting carbamazepine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Definition of the clinical phenotype or implication for a patient with the HLA-A*31:01 allele regarding carbamazepine use\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target FEV1 improvement for an albuterol-treated patient based on their ADRB2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to neomycin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"neomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with neomycin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluticasone nasal spray in pediatric allergic rhinitis patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should milnacipran dosing be adjusted for an individual with the SLC6A4 l/l genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for milnacipran based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should caffeine intake be managed for a patient on clozapine who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target intragastric pH for a pantoprazole-treated patient who is a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of T-cell activation for a nivolumab-treated patient based on their PD-L1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nitrofurantoin in a pregnant patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofurantoin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for nitrofurantoin in pregnant G6PD deficient patients, especially near term.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking naltrexone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using naltrexone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which genotypes correspond to the CYP2C19 normal metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the CYP2C19 normal metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which phenazopyridine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenazopyridine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of phenazopyridine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How is fosphenytoin converted to phenytoin, and what is the role of CYP2C9 in the subsequent metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Mechanism of fosphenytoin conversion and the role of CYP2C9 in phenytoin metabolism\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of mexiletine for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma sufentanil concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for sufentanil stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiovascular side effects with phentermine in individuals with the FTO risk allele for obesity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma pazopanib concentrations in a patient with a specific UGT1A1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended duloxetine dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for duloxetine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for alfentanil in children with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for alfentanil in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of life-threatening respiratory depression with fentanyl in patients with severely reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiovascular mortality with clarithromycin in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is probenecid contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"probenecid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for probenecid in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of hydrocodone therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for hydrocodone's active metabolite, hydromorphone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of early-onset pulmonary events with brigatinib in individuals with reduced CYP2C8 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for propranolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking alfentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of alfentanil in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma propafenone concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the HLA-A gene's role in antigen presentation relate to potential oxcarbazepine hypersensitivity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Basic mechanism of HLA-A in immune-mediated reactions to oxcarbazepine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in limiting the distribution of cetirizine into the brain?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for sotalol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking alfentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for alfentanil in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fentanyl dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for fentanyl based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking toluidine blue?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"toluidine blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with toluidine blue use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma hydromorphone concentrations (from hydrocodone) in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for hydromorphone (active metabolite of hydrocodone) stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sufentanil in patients undergoing surgery with an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for sufentanil in surgical patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 enzyme in the context of metoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on beta-blocker efficacy, particularly in heart failure.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should carvedilol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for carvedilol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperbilirubinemia for a UGT1A1 poor metabolizer taking atazanavir?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atazanavir\", \"Gene Name\": \"UGT1A1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf\", \"Content to Search\": \"Quantified risk data (e.g., odds ratio, incidence rate) of hyperbilirubinemia in UGT1A1 poor metabolizers taking atazanavir.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the biliary excretion of linagliptin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ipilimumab dosing be adjusted for a patient with a specific CTLA-4 gene polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for dibekacin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dibekacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for dibekacin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma morphine concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for morphine stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 ultrarapid metabolizer status affect the plasma concentration of clomipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pharmacokinetic data on clomipramine plasma concentrations in CYP2C19 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial intravenous voriconazole dose for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"voriconazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for intravenous voriconazole in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking fluoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for an imatinib-treated patient based on their ABCG2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A4 poor metabolizers using pitavastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should betaxolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for betaxolol based on ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fentanyl in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for fentanyl adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of alpha-4 integrin saturation for a natalizumab-treated patient based on their ITGA4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to gliclazide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gliclazide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after gliclazide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of HMGCR in the mechanism of action of fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of HMGCR as the pharmacological target of fluvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MAOA genotypes correlate with the cardiovascular side effects of pseudoephedrine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering halothane to a patient with a pathogenic RYR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for halothane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CASR genotypes correlate with the risk of milk-alkali syndrome from calcium carbonate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking phenazopyridine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenazopyridine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with phenazopyridine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for methoxyflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for methoxyflurane in the context of RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for vilazodone based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to fluvoxamine in a patient with the SLC6A4 L/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for fluvoxamine stratified by SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with ibuprofen in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using ibuprofen.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking hydromorphone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using hydromorphone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of HMGCR in the mechanism of action of lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of HMGCR as the pharmacological target of lovastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the minor metabolic pathway of tigecycline?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCC2 genotypes correlate with tenofovir-induced nephrotoxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HTR2A variants are associated with altered desvenlafaxine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of HTR2A variants and their corresponding impact on desvenlafaxine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of G-CSF (filgrastim) for a patient with a specific variant in the CSF3R (G-CSF receptor) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CRBN genotypes correlate with pomalidomide efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of diclofenac for a patient with a UGT2B7*2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking pegloticase?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pegloticase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with pegloticase use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for sumatriptan in a patient with a low-activity MAOA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of promethazine for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sertraline in a pediatric patient with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for sertraline in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for granisetron in a patient with a CYP2D6 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A1 genotypes correlate with pazopanib-induced liver toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to high-dose vitamin C?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin c\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after high-dose vitamin C administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should dextromethorphan dosing be adjusted for a patient who is a CYP2D6 poor metabolizer to avoid psychoactive effects?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sertraline in a pediatric patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for sertraline in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which IFNL4 genotype (rs368234815) corresponds to a favorable response to peginterferon alfa-2a?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Genotype definition (e.g., TT/TT) for the IFNL4 favorable response phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced cardiovascular benefit with empagliflozin in individuals with high-activity UGT2B7 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors correlate with ertapenem-induced seizures?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for ketorolac involving the CYP2C9 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for acebutolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the therapeutic range for the sum of imipramine and desipramine concentrations?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring range for imipramine plus its active metabolite, desipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should digoxin dosing be adjusted based on ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dimercaprol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dimercaprol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with dimercaprol use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended chloroquine dose for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for chloroquine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of carvedilol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with caspofungin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 enzyme in the context of propranolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on propranolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of temsirolimus to sirolimus?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to levomilnacipran for individuals with the HTR2A rs7997012 A allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered levomilnacipran efficacy in patients with the HTR2A rs7997012 A allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Carboxylesterase 1 (CES1) in the bioactivation of olmesartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of NRAS in the EGFR signaling pathway and how do its mutations bypass the need for EGFR activation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2 enzyme in the metabolism of ondansetron?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should pioglitazone dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of metabolic side effects with olanzapine in individuals with low-activity UGT1A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target serum 25(OH)D concentrations for a patient based on their CYP2R1 and GC (VDBP) genotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma oxymorphone concentrations (from oxycodone) in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for oxymorphone (active metabolite of oxycodone) stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific imipramine dosing recommendations for pediatric patients with enuresis who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pediatric dosing guidance for imipramine in CYP2C19 poor metabolizers with enuresis\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for labetalol stratified by ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with GRK4 variants taking betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hematologic toxicity with zidovudine in individuals with low-activity UGT2B7 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with lumiracoxib in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using lumiracoxib.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of peripheral edema with tepotinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a DPYD poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"capecitabine\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Diplotype definitions for the DPYD poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for sonidegib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fosphenytoin in a patient who is positive for the HLA-B*15:02 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Dosing recommendation or alternative therapy for fosphenytoin in HLA-B*15:02 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with pomalidomide in lenalidomide-refractory myeloma patients with acquired CRBN mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is tafenoquine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tafenoquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for tafenoquine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for aprepitant in pediatric patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of bumetanide for a patient with a specific variant in the SLC12A1 (NKCC2) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking aceclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using aceclofenac.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for propranolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for propranolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of abacavir hypersensitivity syndrome (AHS) in an individual carrying the HLA-B*57:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"abacavir\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf\", \"Content to Search\": \"Quantified risk, odds ratio, or incidence rate of AHS in HLA-B*57:01 carriers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking pravastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma simvastatin concentrations in an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for simvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma colchicine concentrations in a patient with a high-activity ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C9 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do germline CD274 genotypes correlate with nivolumab efficacy and immune-related adverse event phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of anxiety and insomnia with armodafinil in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for carvedilol stratified by ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pharmacodynamic data (LDL-C reduction) for simvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ERCC1 polymorphisms correlate with cisplatin efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with the efficacy of ledipasvir/sofosbuvir combination therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma avapritinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does NUDT15 genotype affect the intracellular concentration of thioguanine triphosphate (TGTP)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Pharmacokinetic data on TGTP levels in relation to NUDT15 metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP1A2 genotypes map to altretamine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tamoxifen dosing be adjusted for a patient with the ABCB1 3435C>T variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of asenapine in a patient with a high-activity UGT1A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does NUDT15 poor metabolizer status affect the accumulation of active thioguanine nucleotide (TGN) metabolites from azathioprine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Pharmacokinetic data on TGN concentrations in NUDT15 poor metabolizers after azathioprine administration\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pindolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for pindolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended levomilnacipran dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for levomilnacipran in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Carboxylesterase 1 (CES1) enzyme in the metabolic pathway of clopidogrel?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP3A4 in the metabolism of the corticosteroid mometasone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of chloroquine for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma nadolol concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for nadolol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C9 poor metabolizer phenotype affect the plasma concentration of phenytoin after fosphenytoin administration?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Plasma concentration data for phenytoin in CYP2C9 poor metabolizers after fosphenytoin administration\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions corresponding to the CYP2C19 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of peripheral neuropathy with vincristine in patients who are CYP3A5 non-expressers (*3/*3)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atorvastatin dose for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for atorvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for buspirone when co-administered with a strong CYP3A4 inhibitor, based on a patient's genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2 enzyme in the metabolism of bendamustine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ketoconazole for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of repaglinide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dabrafenib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to fentanyl?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and fentanyl's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for milnacipran in an adolescent with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for milnacipran in adolescents based on HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended oxycodone dose for a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Specific dosing recommendation or contraindication for oxycodone in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to cabozantinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should oxycodone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for oxycodone based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of aceclofenac for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for aceclofenac in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking quinine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"quinine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with quinine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the intestinal absorption and disposition of sofosbuvir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended rosuvastatin dose for an individual with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for rosuvastatin in individuals with SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for desvenlafaxine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the metabolism of amitriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Function of CYP2C19 enzyme in the metabolic pathway of amitriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nausea, vomiting, and mucositis with midostaurin in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CA2 genotypes correlate with topiramate-induced cognitive side effect phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 enzyme in the context of metoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should paclitaxel dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tropisetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding with apixaban in individuals with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of fluoxetine in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluoxetine in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfadiazine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadiazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sulfadiazine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the mechanism of action of sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for sertraline.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should carvedilol dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for carvedilol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced tamoxifen efficacy in individuals with high-activity SULT1A1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should moxifloxacin dosing be adjusted for a patient with a specific KCNH2 (hERG) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of aluminum overload with long-term sucralfate use in renal failure patients with specific transporter gene variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the FCGR2A receptor on macrophages in the therapeutic mechanism of trastuzumab?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nebivolol stratified by ADRB1 Ser49Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended levomilnacipran dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for levomilnacipran in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to amikacin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amikacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with amikacin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for naproxen use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for naproxen in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should lisinopril dosing be adjusted for patients with the ACE DD genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for CYP2D6 poor metabolizers when using tropisetron?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tropisetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for adverse effects in CYP2D6 poor metabolizers taking tropisetron\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A4 enzyme in the glucuronidation and elimination of posaconazole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP1A2 genotypes correspond to desipramine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do HTR2C genotypes correlate with fluoxetine efficacy and side effect phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tepotinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for theophylline in a patient with a specific CYP2E1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for risperidone in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP1A2 genotypes correlate with ondansetron clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trametinib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C19 intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose reduction for fluorouracil in a DPYD intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluorouracil\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Specific dose reduction percentage or value for fluorouracil in DPYD intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to doxycycline metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ADRB1 genotypes correlate with metoprolol efficacy phenotypes in heart failure?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for sunitinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP1A2 define a poor metabolizer in the context of bendamustine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What DPYD activity score corresponds to an intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tegafur\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"DPYD activity score definitions for the intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for albuterol in pediatric asthma patients with the ADRB2 Arg16 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should telmisartan dosing be adjusted for a patient with a UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for labetalol in patients with asthma and an ADRB2 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for labetalol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for nabumetone recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for nabumetone based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the effect of the CYP4F2*3 variant on vitamin K plasma concentrations during warfarin therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP4F2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Data on plasma vitamin K levels in relation to CYP4F2 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should pamidronate dosing be adjusted for a patient with a specific variant in the FDPS gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of penicillin-binding proteins and how do their genetic alterations confer resistance to cefuroxime?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of metoprolol in patients with high-activity GRK4 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of biliary pseudolithiasis with ceftriaxone in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do the vanA, vanB, and vanC genotypes in Enterococcus species correlate with the level of vancomycin resistance?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a NAT2 slow acetylator for procainamide therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sulfadiazine in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadiazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for sulfadiazine in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of idelalisib's main metabolite, GS-563117, in a patient with a high-activity UGT1A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of citalopram in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for citalopram in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sulfacetamide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfacetamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sulfacetamide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using vilazodone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking pravastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma zolpidem concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 receptor in the mechanism of action of esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A6 enzyme in the detoxification of acetaminophen?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with GRK4 variants taking acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should colchicine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A8 genotypes correlate with sitagliptin renal clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should esmolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for esmolol based on GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of fatal toxicity when colchicine is co-administered with a strong CYP3A4 inhibitor in a patient who is also a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 enzyme in the context of pindolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on pindolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dupilumab for a patient with a specific variant in the IL4R (interleukin-4 receptor) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with nabumetone in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using nabumetone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which rasburicase causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rasburicase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of rasburicase-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should carvedilol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for carvedilol based on ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should atenolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for atenolol based on ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking simvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should codeine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for codeine based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mesalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of treatment failure with tamoxifen in individuals with high-activity ABCB1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to naltrexone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and naltrexone's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tolbutamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolbutamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with tolbutamide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma itraconazole concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of acebutolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the beta-2 adrenergic receptor and its interaction with acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should quinapril dosing be adjusted for a patient with the ACE II genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the CDK4/6 inhibitor ribociclib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'low-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of lumiracoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in lumiracoxib's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response to mepolizumab in severe eosinophilic asthma patients with low-affinity IL5RA variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MAOA/MAOB genotypes correlate with procarbazine's side effect profile?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sufentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for sufentanil based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to trametinib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trametinib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after trametinib administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking lovastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for zidovudine-glucuronide in a patient with a high-activity UGT2B7 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking nabumetone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using nabumetone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of milnacipran in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for milnacipran in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for vemurafenib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for pindolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended lovastatin dose for an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for lovastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the DIO2 genotype correspond to T4 to T3 conversion efficiency phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of imatinib for a patient with the ABCG2 Q141K variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ENaC channel, the target of amiloride, and how do its variants alter drug action?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors correlate with amphotericin B-induced infusion reactions?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to escitalopram in a patient with the SLC6A4 L/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for escitalopram stratified by SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ocrelizumab dosing be adjusted for a patient with a specific FCGR3A V158F polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypertension and fatigue with axitinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'normal-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with fexofenadine bioavailability phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mesalazine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mesalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with mesalazine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for carfilzomib based on a patient's proteasome subunit genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of hydromorphone in a CYP2D6 poor metabolizer after a standard dose of hydrocodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration data for hydromorphone (the active metabolite of hydrocodone) in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of prolonged sedation with diazepam in CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for piroxicam dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for piroxicam therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of escitalopram in a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for escitalopram in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pitavastatin dose for an individual with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pitavastatin in individuals with SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which toluidine blue causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"toluidine blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of toluidine blue-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of saxagliptin's active metabolite in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of vasodilation for a nitroglycerin-treated patient based on their ALDH2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define SLCO1B1 normal function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding function scores for the SLCO1B1 normal function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadiazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of fluoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's primary role in the metabolic pathway of fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OAT1 transporter in the active tubular secretion of acyclovir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which gliclazide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gliclazide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of gliclazide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nephrotoxicity with amphotericin B in individuals with genetic predispositions to renal dysfunction?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to budesonide clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of myopathy with atorvastatin in patients carrying DPYD deficiency alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking furazolidone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"furazolidone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with furazolidone use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking desvenlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking remifentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for remifentanil in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which tolazamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolazamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of tolazamide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of C. difficile infection with clindamycin in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with sofosbuvir efficacy phenotypes in Hepatitis C treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A4 genotypes correlate with olanzapine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of Factor V Leiden and its impact on the coagulation cascade, independent of warfarin's action on vitamin K?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (encoded by ABCB1) in the intestinal absorption of simvastatin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific tamoxifen dosing considerations for postmenopausal CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tamoxifen\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf\", \"Content to Search\": \"Dosing or therapy recommendations for postmenopausal CYP2D6 poor metabolizers on tamoxifen\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for remifentanil in patients undergoing surgery with an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for remifentanil in surgical patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should axitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for propranolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for propranolol in patients of African ancestry, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for lurasidone in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sulfanilamide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfanilamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sulfanilamide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in celecoxib exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on celecoxib exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma sonidegib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of cimetidine's inhibition of the CYP2D6 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of HMGCR in the mechanism of action of simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of HMGCR as the pharmacological target of simvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the SVR rate for patients with the favorable IFNL4 TT/TT genotype when treated with peginterferon alfa-2b?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Quantified SVR rates for peginterferon alfa-2b therapy in patients with the favorable IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for kanamycin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"kanamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for kanamycin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of colchicine toxicity (e.g., myelosuppression) in patients with specific ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hematologic toxicity with olaparib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dacarbazine for a patient with an unmethylated MGMT promoter in their tumor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should gemfibrozil dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfacetamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfacetamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sulfacetamide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma praziquantel concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pharmacodynamic data (LDL-C reduction) for lovastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with GRK4 variants taking labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hand-foot syndrome with sunitinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma vilazodone concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for vilazodone in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of prolonged postoperative respiratory depression with alfentanil in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyponatremia with indapamide in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for trabectedin in sarcoma patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should hydralazine dosing be adjusted for a patient with a NAT2 slow acetylator genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of sorafenib for a patient who is a UGT1A9 promoter polymorphism carrier?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target serum calcium level for a patient taking calcium carbonate based on their CASR genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as heart rate changes, for metoprolol stratified by ADRB1 Ser49Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with zanamivir in infections caused by influenza with the H275Y NA mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for primaquine for malaria prophylaxis in a G6PD deficient child?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"primaquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for primaquine in G6PD deficient children for malaria treatment or prophylaxis.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nalidixic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for lamotrigine in a patient with a high-activity UGT1A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of bisoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the beta-2 adrenergic receptor and its interaction with bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of supratherapeutic tacrolimus concentrations for a CYP3A5 non-expresser (poor metabolizer)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tacrolimus\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf\", \"Content to Search\": \"Quantified risk of toxicity or supratherapeutic concentrations in CYP3A5 poor metabolizers taking tacrolimus\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in preventing loperamide from crossing the blood-brain barrier?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for betaxolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperbilirubinemia with dolutegravir in individuals with reduced UGT1A1 function (Gilbert's syndrome)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for levomilnacipran in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2B6 enzyme contribute to the metabolism of methadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2B6's role in methadone's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A9 genotypes map to canagliflozin glucuronidation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for trazodone therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 gene product in the context of labetalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for phenazopyridine in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenazopyridine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for phenazopyridine in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of taste disturbance with terbinafine in patients with reduced CYP2D6 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the proposed immunological mechanism for HLA-B*15:02-mediated carbamazepine hypersensitivity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Mechanism of HLA-B*15:02 involvement in the immune response to carbamazepine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for lopinavir in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is toluidine blue contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"toluidine blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for toluidine blue in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of labetalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma sufentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for sufentanil stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism of action of ribavirin and how does it synergize with the IFNL3-related interferon response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Interaction between ribavirin's mechanism and the IFNL3-mediated immune pathway\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A4 poor metabolizers using simvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with standard dexlansoprazole dosing for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dexlansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using dexlansoprazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered levomilnacipran response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of SLC6A4 variants and their corresponding impact on levomilnacipran response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tiotropium dosing be adjusted for a patient with a specific cholinergic receptor (CHRM3) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to nitrofurantoin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofurantoin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after nitrofurantoin administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the TPMT enzyme in shunting azathioprine metabolites away from the active cytotoxic pathway?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Role of the TPMT enzyme in the inactivation pathway of azathioprine metabolites\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pravastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pravastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should amiloride dosing be adjusted for a patient with a specific variant in the SCNN1A (ENaC alpha subunit) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of ibuprofen for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for ibuprofen in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for acyclovir in a patient with a high-function OAT1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfamethoxazole / trimethoprim\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fluvoxamine dosing be adjusted for an individual with the SLC6A4 L/L genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for fluvoxamine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A9 enzyme in the metabolism of dapagliflozin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atomoxetine in adults with ADHD and a known CYP2D6 poor metabolizer status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor cognitive response to donepezil in individuals with ACHE variants that alter enzyme structure?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of bosutinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of anticholinergic side effects (e.g., dry mouth, confusion) with oxybutynin in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A9 enzyme in the metabolism of mycophenolic acid?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of osimertinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do GADL1 genotypes correlate with lithium efficacy phenotypes in bipolar disorder?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with loratadine efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the pharmacokinetics of simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of ABCG2's role as an efflux transporter affecting simvastatin disposition.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended levomethadone dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for levomethadone in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should labetalol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for labetalol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nicorandil in a cardiac patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nicorandil\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for nicorandil in G6PD deficient patients with angina.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ramipril in post-MI patients based on their ACE I/D polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bendamustine dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of deoxycytidine kinase (DCK) in the phosphorylation and activation of cladribine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should idelalisib dosing be adjusted for a patient with a UGT1A4*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target intracellular concentrations of the active sofosbuvir triphosphate metabolite based on a patient's ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A5 enzyme in the metabolism of pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A5's role in pitavastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for flurbiprofen recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for flurbiprofen based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP2D6 define a poor metabolizer in the context of cimetidine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes map to clonidine metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of bacterial nitroreductases in the activation of the prodrug nitrofurantoin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for spironolactone therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma procarbazine concentrations based on MAO genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended codeine dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for codeine in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should labetalol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for labetalol based on GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vancomycin dosing be adjusted for a patient with a specific variant in the D-Ala-D-Lac synthesis pathway genes (vanA, vanB)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CES2 genotype correlate with the hydrolysis of the prodrug ciclesonide to its active form?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma infigratinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to finasteride for benign prostatic hyperplasia in individuals with specific SRD5A2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for avapritinib in GIST patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'low-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for succinylcholine in a patient with RYR1-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for succinylcholine in the context of RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of ibuprofen?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in ibuprofen's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of theophylline for a patient with a CYP1A2*1D/*1F genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of celecoxib for a patient with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of seizures with enzalutamide in individuals with reduced CYP2C8 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking morphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for morphine in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of metformin intolerance in individuals with low-function MATE1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for halothane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for halothane in patients with RYR1-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose reduction of cisplatin for a patient with TPMT deficient alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP1A2 genotypes map to ropinirole clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in flurbiprofen exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on flurbiprofen exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for sotalol stratified by ADRB1 Ser49Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'high-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected area under the curve (AUC) for rabeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rabeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on rabeprazole exposure in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the 5-HT2C receptor (HTR2C) and how might its variants alter the effects of fluoxetine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for methoxyflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for methoxyflurane in patients with RYR1-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for clonazepam in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pindolol dose for an individual with the GRK5 Gln41Leu polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for pindolol based on GRK5 Gln41Leu genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target therapeutic range for plasma phenytoin concentrations?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Therapeutic window or plasma concentration range for phenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for acebutolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for acebutolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for esmolol stratified by ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for bisoprolol in patients with hypertension and a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for bisoprolol in hypertensive patients, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a known pharmacokinetic interaction between abacavir and the HLA-B*57:01 allele, or is the mechanism purely immunological?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"abacavir\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf\", \"Content to Search\": \"Pharmacokinetic data or description of the immunological mechanism for abacavir hypersensitivity related to HLA-B*57:01\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes map to gefitinib metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of myopathy with simvastatin in patients with low-activity ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of piroxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in piroxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvastatin dose for an individual with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvastatin in individuals with SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nadolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for nadolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking levomilnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of esmolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the beta-2 adrenergic receptor and its interaction with esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FDPS genotypes correlate with pamidronate efficacy in treating Paget's disease of bone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of anagrelide for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which NUDT15 alleles are most commonly associated with an intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Allele definitions for the NUDT15 intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should carvedilol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for carvedilol based on GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is methylene blue contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methylene blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for methylene blue in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ibuprofen for a patient with a TPMT poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking duloxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of excessive diuresis and electrolyte imbalance with torsemide in patients with CYP2C9*2 or *3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for plazomicin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"plazomicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for plazomicin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for desflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for desflurane in patients with RYR1-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP1A2 diplotypes correspond to the ultrarapid metabolizer phenotype for warfarin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of pindolol in patients with the ADRB1 Arg389Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should irinotecan dosing be adjusted for a patient with the UGT1A1*28/*28 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation and skin reactions with vandetanib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the therapeutic window for plasma 9-hydroxyrisperidone in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for using sodium nitrite for cyanide poisoning in a G6PD deficient patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sodium nitrite\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for using sodium nitrite as a cyanide antidote in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Signal Transducer and Activator of Transcription 1 (STAT1) in the interferon signaling pathway?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to hydroxychloroquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydroxychloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after hydroxychloroquine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the RYR1 gene in the mechanism of sevoflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the RYR1 gene function and its role in the pathophysiology of sevoflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for vortioxetine based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of respiratory depression with fentanyl in patients with the ABCB1 3435C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for ticagrelor therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for levetiracetam in a patient based on their SV2A genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to glimepiride?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glimepiride\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after glimepiride administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of codeine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for codeine's active metabolite, morphine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should metformin dosing be adjusted for a patient with a specific variant in the ATM gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of erythromycin's potent inhibition of the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvastatin dose for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target plasma concentration range for nortriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Therapeutic drug monitoring range for nortriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to risperidone clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the MET inhibitor capmatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CDA genotypes correlate with cytarabine clearance and toxicity phenotypes in acute myeloid leukemia (AML)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe diarrhea/colitis and hepatotoxicity with idelalisib in individuals with low-activity UGT1A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which MTHFR diplotypes are associated with increased methotrexate toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomilnacipran in adolescents with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for levomilnacipran in adolescent patients, adjusted for HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in venlafaxine users with the HTR2A rs6313 G/G genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in naproxen exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on naproxen exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Should ribavirin dosing be modified in a peginterferon regimen based on the patient's IFNL4 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Ribavirin dose adjustment protocol based on IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atorvastatin dose for an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for atorvastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking fluvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested QTc interval limit for a sotalol-treated patient based on their KCNH2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of arterial occlusive events with ponatinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the ABCB1 genotype correspond to tacrolimus dose requirement phenotypes in kidney transplant patients?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfacetamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a recommended dosing adjustment for nortriptyline based on CYP2C19 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for nortriptyline based on CYP2C19 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the doxepin dosing recommendation for a patient who is both a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing guidance for doxepin in patients with combined CYP2D6 and CYP2C19 ultrarapid metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2C9 in the metabolism of zafirlukast and its potential to inhibit other CYP enzymes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for olanzapine in a patient with a CYP1A2 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal side effects (e.g., nausea) with semaglutide in individuals with specific GLP1R variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of visual disturbances with sildenafil in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the N-acetyltransferase 2 (NAT2) enzyme in the metabolism of sulfapyridine, the active moiety of sulfasalazine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking buprenorphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using buprenorphine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of altered ledipasvir exposure in individuals with specific ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target blood pressure reduction for an HCTZ-treated patient based on their ADD1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which quinine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"quinine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of quinine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP1A2*1F allele in the context of warfarin metabolism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do GSTP1 genotypes correlate with carmustine resistance phenotypes in brain tumors?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should clindamycin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neurotoxicity from fosphenytoin in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for neurotoxicity in CYP2C9 poor metabolizers using fosphenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should avapritinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ziprasidone dosing be adjusted for a patient who is a CYP3A4 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of pneumonitis and hypertension with pralsetinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for bevacizumab based on a patient's germline VEGF-A genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ACE genotypes map to ramipril efficacy phenotypes in preventing cardiovascular events?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for inhaled tobramycin in cystic fibrosis patients with a known MT-RNR1 risk variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP3A4 in the primary metabolic pathway of albendazole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe rash (Stevens-Johnson syndrome) with nevirapine in patients with specific CYP2B6 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered citalopram response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of SLC6A4 variants and their corresponding impact on citalopram response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for lumiracoxib dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for lumiracoxib therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended therapeutic alternative to clopidogrel for a CYP2C19 poor metabolizer undergoing percutaneous coronary intervention (PCI)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clopidogrel\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf\", \"Content to Search\": \"Alternative antiplatelet therapy recommendations for CYP2C19 poor metabolizers post-PCI.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypertension and QTc prolongation with selpercatinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of venlafaxine in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for venlafaxine in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vilazodone in an adolescent with the SLC6A4 s/s genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for vilazodone in adolescents based on SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for neomycin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"neomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for neomycin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target cerebrospinal fluid concentrations of citalopram for a patient with the ABCB1 3435C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering desflurane to a patient with a pathogenic RYR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for desflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lorlatinib in ALK-positive lung cancer patients with known CYP3A4 variants, especially when co-administered with strong CYP3A4 inducers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of morphine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in morphine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of lactic acidosis for metformin users who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dapsone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dapsone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with dapsone use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of trabectedin for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for sufentanil involving the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in paroxetine users with the HTR2A rs6313 G/G genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which ofloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of ofloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of desvenlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in the metabolic pathway of desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of pindolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on pindolol effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended morphine dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for morphine in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SULT2A1 genotypes correlate with abiraterone efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced efficacy of sublingual nitroglycerin for angina in individuals with the ALDH2*2 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered duloxetine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of SLC6A4 variants and their corresponding impact on duloxetine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should levomethadone dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for levomethadone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for acebutolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for acebutolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which ABCB1 genotypes are associated with paclitaxel resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target blood pressure reduction for a chlorthalidone-treated patient based on their SLC12A3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking ciprofloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ciprofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with ciprofloxacin use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of candesartan for a patient with a specific variant in the AGTR1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for methadone in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for methadone in opioid use disorder patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of acebutolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ceftriaxone concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma erythromycin concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CACNA1S gene in the mechanism of methoxyflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the CACNA1S gene function and its role in the pathophysiology of methoxyflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for nabumetone dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for nabumetone therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (SLCO1B1) in the hepatic disposition of rivaroxaban?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atenolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for atenolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP2C9 poor metabolizers using atorvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the serotonin transporter's (SERT) role as the primary target of milnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should naltrexone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for naltrexone based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the KIT/PDGFRA inhibitor ripretinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering enflurane to a patient with a pathogenic CACNA1S variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for enflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sertraline in an adolescent with the SLC6A4 s/s genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for sertraline in adolescents based on SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of naproxen for a patient identified as a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tolazamide in a diabetic patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolazamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for tolazamide in G6PD deficient patients with type 2 diabetes.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribostamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should niacin dosing be adjusted for a patient with a specific HCAR2 (GPR109A) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking simvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of nebivolol in patients with the ADRB2 Gln27Glu polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the CPIC-recommended dose for metformin in a patient with the CYP2D6 *4/*4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tafenoquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of CNS side effects with indomethacin in individuals who are poor metabolizers via UGT2B7?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HTR2A variants are associated with altered citalopram response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of HTR2A variants and their corresponding impact on citalopram response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for duloxetine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pitavastatin concentrations in a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pitavastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do bacterial MurA genotypes correlate with fosfomycin resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of vilazodone in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for vilazodone in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sulfisoxazole causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfisoxazole\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sulfisoxazole-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended simvastatin dose for an individual with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for simvastatin in individuals with SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the multi-kinase inhibitor lenvatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should pralsetinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of fentanyl for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MT-RNR1 genotypes map to aminoglycoside-induced toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2E1 enzyme in the metabolic pathway of theophylline?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma guanfacine concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended naltrexone dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for naltrexone in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do bacterial nitroreductase genotypes correlate with nitrofurantoin resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Programmed Cell Death Protein 1 (PD-1), the target of pembrolizumab, and how do its variants alter immune checkpoint regulation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor antidepressant response to fluoxetine in individuals carrying the BDNF Met allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding for warfarin patients with low-activity CYP1A2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of quetiapine treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of nebivolol in patients with high-activity GRK4 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of O-desmethyltramadol in a CYP2D6 poor metabolizer after a standard dose of tramadol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration data for O-desmethyltramadol (the active metabolite of tramadol) in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma O-desmethylvenlafaxine concentrations in a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges for O-desmethylvenlafaxine in CYP2C19 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for rosiglitazone in a patient with a CYP2C8 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of nucleoside transporters in the uptake of fludarabine into target cells?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 rapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dexlansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions corresponding to the CYP2C19 rapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for ribostamycin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribostamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for ribostamycin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is vitamin K contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin k\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for vitamin K in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should indapamide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma lovastatin concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for lovastatin in CYP2C9 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dose adjustment for pantoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pantoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidance for pantoprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chloroquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with chloroquine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma simvastatin concentrations in an individual with SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for simvastatin in individuals with SLCO1B1 intermediate function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rosuvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for rosuvastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of O-desmethyltramadol toxicity for a CYP2D6 ultrarapid metabolizer taking tramadol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk, incidence rate, or odds ratio for O-desmethyltramadol toxicity in CYP2D6 UMs using tramadol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sertraline dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for sertraline in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with artemether-lumefantrine in individuals who are CYP3A4 rapid metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do NAT2 genotypes map to isoniazid acetylation and clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sirolimus dosing be adjusted for a patient who is a CYP3A5 expresser?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for abemaciclib and its active metabolites in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with phenytoin response phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking esmolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking esmolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does CYP2C19 genotype significantly alter the plasma concentrations of nortriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pharmacokinetic data on the impact of CYP2C19 genotype on nortriptyline plasma levels\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for esmolol in patients with heart failure and a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for esmolol in heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP1A2 enzyme in the N-demethylation of desipramine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for olmesartan in a patient with a low-activity CES1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for norfloxacin in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"norfloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for norfloxacin in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking fentanyl?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using fentanyl.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking escitalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should carvedilol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for carvedilol based on ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for diazepam in elderly patients with the CYP2C19*2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the dual 5-alpha reductase inhibitor dutasteride?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the IFNL4-ΔG variant that leads to impaired viral clearance during peginterferon alfa-2a therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Mechanism of the IFNL4-ΔG variant and its impact on interferon signaling or response\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pitavastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pitavastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma telmisartan concentrations in a patient with a specific UGT1A1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for paromomycin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paromomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for paromomycin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CRBN genotypes correlate with thalidomide efficacy and teratogenicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes map to rosuvastatin metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in meloxicam exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on meloxicam exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of buspirone for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 gene product in the context of atenolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of persistent hypothyroid symptoms on levothyroxine in individuals with the DIO2 Thr92Ala variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for piroxicam use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for piroxicam in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended hydroxychloroquine dose for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydroxychloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for hydroxychloroquine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxorubicin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended escitalopram dose for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol or alternative medication recommendation for escitalopram in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there different treatment recommendations with peginterferon alfa-2a for patients with HIV/HCV coinfection based on their IFNL3 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Specific recommendations for peginterferon alfa-2a in HIV/HCV coinfected patients stratified by IFNL3 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluvoxamine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pitavastatin dose for an individual with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pitavastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vitamin K in a G6PD deficient neonate?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin k\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for vitamin K administration to G6PD deficient newborns.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2D6 in the metabolic clearance of tamsulosin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer for irbesartan therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which dapsone causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dapsone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of dapsone-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Torsades de Pointes with sotalol in individuals with congenital long QT syndrome caused by KCNH2 mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the FCGR3A receptor on NK cells in mediating antibody-dependent cell-mediated cytotoxicity (ADCC) for rituximab?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in sertraline users with the HTR2A rs6313 G/G genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tobramycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking oxycodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of oxycodone in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ofloxacin in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for ofloxacin in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A5 normal metabolizers using simvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering ribostamycin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribostamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for ribostamycin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of anagrelide's active metabolite, 3-hydroxy anagrelide, in a patient with a CYP1A2 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with acetaminophen overdose in individuals with low-activity SULT1A1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of bradycardia for sufentanil users with decreased CYP3A4 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should galantamine dosing be adjusted for a patient who is both a CYP2D6 and CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sitagliptin dosing be adjusted for a patient with a specific organic anion transporter (OAT3/SLC22A8) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for efavirenz in a patient with a CYP2A6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma hydromorphone concentrations (from hydrocodone) in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for hydromorphone (active metabolite of hydrocodone) stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to ciprofloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ciprofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after ciprofloxacin administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for meloxicam dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for meloxicam therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should esmolol dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for esmolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do GLP1R genotypes correlate with liraglutide efficacy and its risk for pancreatitis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for lovastatin involving the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fentanyl dosing be adjusted for a patient with low-function ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor LDL-lowering response to ezetimibe in individuals with specific NPC1L1 polymorphisms?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of respiratory depression with codeine in patients with reduced CYP3A4 function when co-administered with a CYP2D6 inhibitor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C19 ultrarapid metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in milnacipran users with the SLC6A4 s/s genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the CPIC dosing recommendation for risperidone in pediatric patients who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for vancomycin when treating an infection with a known vanA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should probenecid dosing be adjusted for a patient with a low-function OAT1 (SLC22A6) genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering sevoflurane to a patient with a pathogenic CACNA1S variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for sevoflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested level of platelet inhibition for a clopidogrel-treated patient based on their CES1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for pralsetinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected area under the curve (AUC) for dexlansoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dexlansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on dexlansoprazole exposure in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for oxybutynin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should trazodone dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which aspirin causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of aspirin-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dimercaprol contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dimercaprol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for dimercaprol in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of diclofenac-acyl-glucuronide in a patient with a high-activity UGT2B7 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of desvenlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in the metabolic pathway of desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with naproxen in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using naproxen.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should gliclazide dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there any recommended dosing adjustment for desipramine based on CYP2C19 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for desipramine based on CYP2C19 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in paroxetine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of vortioxetine in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for vortioxetine in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for morphine in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for morphine in cancer patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of irreversible ototoxicity (hearing loss) with gentamicin in individuals with the m.1555A>G mutation in MT-RNR1?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of thalidomide for a patient with a specific variant in the CRBN (cereblon) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for gentamicin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gentamicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for gentamicin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of ketoconazole's potent inhibition of the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma gemfibrozil concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dose adjustment for dexlansoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dexlansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidance for dexlansoprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CES2 genotype correlate with the conversion of capecitabine to 5'-DFCR phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for paclitaxel in patients with ABCB1 variants and hepatic impairment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for sildenafil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gentamicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CACNA1S gene in the mechanism of desflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the CACNA1S gene function and its role in the pathophysiology of desflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should pramipexole dosing be adjusted for a patient with a low-function SLC22A2 (OCT2) genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of sedation with cetirizine in individuals with specific ABCB1 variants that increase CNS penetration?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define ABCG2 normal function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the ABCG2 normal function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to buprenorphine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CES1 genotype correlate with the hydrolysis of methylphenidate to its inactive metabolite?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which the HLA-B*15:02 allele is thought to trigger an adverse immune response to fosphenytoin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fosphenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Immunological mechanism of HLA-B*15:02-mediated adverse reaction to fosphenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atorvastatin in pediatric patients with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for atorvastatin adjusted for SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for transdermal granisetron in patients with a CYP2D6 gene duplication?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of lumiracoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on lumiracoxib exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using vilazodone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperkalemia with amiloride in individuals with variants causing Liddle syndrome?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma concentrations of N-desethyloxybutynin in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of the sulfonylurea gliclazide?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a known pharmacokinetic mechanism linking HLA-A*31:01 to carbamazepine-induced adverse reactions?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Pharmacokinetic data or mechanism linking HLA-A*31:01 and carbamazepine adverse events\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tobramycin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tobramycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for tobramycin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CTLA-4 genotypes correlate with ipilimumab efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR).\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A4's role in lovastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for midostaurin therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma levomethadone concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for levomethadone in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of serotonin syndrome when linezolid is co-administered with an SSRI in a patient with a low-activity MAOA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is pegloticase contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pegloticase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for pegloticase in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of postural hypotension with maraviroc in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2D6 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should zanamivir dosing be adjusted for a patient with a specific neuraminidase (NA) gene variant in the infecting influenza virus?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to fluvoxamine for individuals with the HTR2A rs7997012 A allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered fluvoxamine efficacy in patients with the HTR2A rs7997012 A allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to lapatinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer for tropisetron therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for isoflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for isoflurane in the context of RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation with ziprasidone in a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of citalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of SLC6A4's role as the serotonin transporter, the primary target of citalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of terbinafine and its potential for inhibiting the metabolism of other drugs?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfanilamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the IFNL3 genotype affect the viral kinetics during treatment with peginterferon alfa-2a?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Pharmacodynamic data on viral load reduction based on IFNL3 genotype during peginterferon alfa-2a treatment\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with standard esomeprazole dosing for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esomeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using esomeprazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of lopinavir/ritonavir for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of midazolam for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target QTc interval for a dofetilide-treated patient, and how is that decision influenced by KCNH2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested intracellular concentrations of fludarabine triphosphate based on a patient's transporter genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of mirtazapine for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation for a CYP2D6 poor metabolizer taking desipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of QTc prolongation in CYP2D6 poor metabolizers on desipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvoxamine dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol or alternative medication recommendation for fluvoxamine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for desvenlafaxine in adolescents with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for desvenlafaxine in adolescent patients, adjusted for HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nicorandil\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with rivaroxaban peak concentration phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using vortioxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking hydromorphone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for hydromorphone in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended metoprolol dose for an individual with the GRK5 Gln41Leu polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for metoprolol based on GRK5 Gln41Leu genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to rituximab in lymphoma patients who are homozygous for the low-affinity FCGR3A-158F allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of aceclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in aceclofenac's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to bosutinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of piroxicam for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for piroxicam in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for argatroban in patients with a genetic predisposition to liver disease?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering paromomycin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paromomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for paromomycin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should furosemide dosing be adjusted based on SLC12A1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glimepiride?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glimepiride\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with glimepiride use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of levodopa for a patient with a COMT Val158Met polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A4's role in simvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to furazolidone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"furazolidone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after furazolidone administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma simvastatin concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for simvastatin in CYP2C9 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of atorvastatin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in the disposition of omeprazole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sodium nitrite?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sodium nitrite\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sodium nitrite administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with high-dose aspirin in patients with reduced-function CYP2C9 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Risk data for adverse effects with high-dose aspirin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe immune-related adverse events (irAEs) with ipilimumab in individuals with specific CTLA-4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which chloroquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"chloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of chloroquine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do PNLIP genotypes correlate with orlistat efficacy and gastrointestinal side effect phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ipratropium for a patient with a specific cholinergic receptor (CHRM3) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cefepime for a patient with a genetic predisposition to neurotoxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the extensive first-pass metabolism of praziquantel?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of secondary failure of glimepiride therapy in individuals with the KCNJ11 E23K polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the ACE I/D polymorphism correlate with lisinopril efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lovastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for lovastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for trametinib in a cancer patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trametinib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for trametinib in G6PD deficient cancer patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the MGMT enzyme in reversing the therapeutic DNA damage caused by dacarbazine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of capillary leak syndrome with high-dose IL-2 in individuals with specific IL2RA variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role as the primary metabolizing enzyme for metoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of duloxetine in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for duloxetine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role, if any, of the CYP2C19 enzyme in the metabolism of nortriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Function of CYP2C19 enzyme in the metabolic pathway of nortriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for desipramine in a CYP1A2 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pitavastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pitavastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma hydralazine concentrations in a NAT2 rapid acetylator?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to entrectinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for oxycodone in a patient with a specific ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the NCC transporter (encoded by SLC12A3), the direct target of chlorthalidone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target HbA1c or weight reduction for a semaglutide-treated patient based on their GLP1R genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe toxicity for a DPYD poor metabolizer taking capecitabine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"capecitabine\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Quantified risk data for severe toxicity in DPYD poor metabolizers using capecitabine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of adducin 1 and its role in sodium transport as it relates to HCTZ's mechanism of action?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended initial dose of indomethacin for a patient with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for indomethacin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfanilamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfanilamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sulfanilamide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolic pathway of clonazepam?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OCT2 transporter (encoded by SLC22A2) in the renal excretion of gabapentin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for mirtazapine in geriatric patients with a CYP2D6 decreased function allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP2C9's role in fluvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cetuximab for a patient with a specific KRAS gene mutation in their tumor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should glasdegib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for tobramycin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tobramycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for tobramycin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of citalopram in a CYP2B6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for citalopram in CYP2B6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for using topical mafenide on a burn patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mafenide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for topical mafenide use in G6PD deficient burn patients, considering systemic absorption.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of penicillin-binding proteins and how do their genetic alterations in bacteria confer resistance to amoxicillin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nadolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nadolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the metabolism of the IDH2 inhibitor enasidenib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for bisoprolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for bisoprolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in dopamine regulation and its potential interaction with paroxetine's therapeutic mechanism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for plazomicin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"plazomicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for plazomicin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for succinylcholine in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for succinylcholine in patients with CACNA1S-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 gene product in the context of carvedilol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target therapeutic range for plasma linagliptin in a patient with a low-function ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A9 genotypes map to sorafenib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target blood pressure reduction for a carvedilol-treated patient based on their ADRB2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of pulmonary toxicity with carmustine in individuals with low-activity GSTP1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of duloxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A4 genotypes map to posaconazole clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naproxen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in venlafaxine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for glimepiride in a diabetic patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glimepiride\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for glimepiride in G6PD deficient patients with type 2 diabetes.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the phenotype assignment for a patient with one normal function and one no function NUDT15 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Phenotype category for a heterozygous NUDT15 no function allele carrier\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for eszopiclone involving the CYP3A4 enzyme?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of atrioventricular block with diltiazem in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the ABCG2 decreased function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended milnacipran dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for milnacipran in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to levomilnacipran in a patient with the SLC6A4 L/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for levomilnacipran stratified by SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pitavastatin concentrations in an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pitavastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of non-response to loratadine in patients with high-activity ABCB1 transporter function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in indomethacin exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on indomethacin exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking carvedilol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is mepacrine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mepacrine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for mepacrine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the phenotype assignment for a patient with a TPMT*1/*3A diplotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Phenotype category (intermediate metabolizer) for the TPMT*1/*3A diplotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should capecitabine dosing be adjusted for a patient with a CES2 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neurotoxicity with fludarabine in individuals with genetic variants affecting drug transport or metabolism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the hERG potassium channel and how is it affected by moxifloxacin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism of vancomycin resistance conferred by the vanA gene cluster?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should lomustine (CCNU) dosing be adjusted for a patient with an unmethylated MGMT promoter in their tumor?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for amikacin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amikacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for amikacin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for benazeprilat based on a patient's ACE genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfisoxazole\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the clinical phenotype associated with being an HLA-B*57:01 carrier in the context of abacavir therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"abacavir\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf\", \"Content to Search\": \"Definition of the clinical implication or phenotype for an HLA-B*57:01 carrier regarding abacavir use\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nebivolol stratified by ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for crizotinib in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for morphine in children with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for morphine in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the imipramine dosing recommendation for a patient who is a CYP2D6 poor metabolizer and also has renal impairment?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing guidance for imipramine in patients with both CYP2D6 poor metabolizer status and renal impairment\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended metoprolol dose for an individual with the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for metoprolol based on ADRB2 Gly16Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for aspirin recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for aspirin based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of organic anion transporters (OATs) in the active tubular secretion of piperacillin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough plasma concentrations for flecainide in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Fanconi syndrome and renal toxicity with TDF in individuals with low-function ABCC2 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for diclofenac dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for diclofenac therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperkalemia with spironolactone in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for liposomal amphotericin B in pediatric patients with a genetic susceptibility to renal damage?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of gemcitabine for a patient with a CDA (cytidine deaminase) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should esmolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for esmolol based on ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered milnacipran response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definitions of HTR2A genotypes and their association with milnacipran efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should paclitaxel dosing be adjusted for a patient with low-function ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do IL4R genotypes correlate with dupilumab efficacy phenotypes across Type 2 inflammatory diseases?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CES1 genotype correlate with the hydrolysis of the prodrug olmesartan medoxomil?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should meropenem dosing be adjusted for a patient with a specific variant affecting renal tubular secretion transporters like OAT1/OAT3?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response timeline for a fluoxetine-treated patient based on their BDNF genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of salmeterol for a patient with the ADRB2 Arg16Gly polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should montelukast dosing be adjusted for a CYP2C8*3 carrier?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atenolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for atenolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of lovastatin treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A5 normal metabolizers using pravastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target peak and trough concentrations for amikacin in a patient with a high-risk MT-RNR1 genotype, assuming the drug must be used?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the context of desvenlafaxine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the F5 G1691A polymorphism correlate with warfarin resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of aspirin for a patient with the PTGS1 (COX-1) -1676A>G polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for esmolol in patients with asthma and an ADRB2 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for esmolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for lumiracoxib recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lumiracoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for lumiracoxib based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ramelteon dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do PBP genotypes in bacteria correlate with amoxicillin resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is ofloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for ofloxacin in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for betaxolol in patients with hypertension and a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for betaxolol in hypertensive patients, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should maraviroc dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should ezetimibe dosing be adjusted for a patient with a NPC1L1 gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma colchicine concentrations in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking hydroxychloroquine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydroxychloroquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with hydroxychloroquine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for metformin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with diclofenac in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using diclofenac.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using venlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of mexiletine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended desvenlafaxine dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for desvenlafaxine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for eplerenone in heart failure patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do viral NA genotypes correlate with zanamivir resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking amitriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using amitriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should capecitabine dosing be adjusted for a DPYD intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"capecitabine\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Dose adjustment protocol for capecitabine in DPYD intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nebivolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for nebivolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of propranolol in patients with high-activity GRK4 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for codeine in pediatric patients post-tonsillectomy with an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for codeine in pediatric post-tonsillectomy patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of orthostatic hypotension for quetiapine users with decreased CYP3A4 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of sotalol in patients with the ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a NUDT15 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Diplotype definitions for the NUDT15 poor metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do proteasome subunit genotypes correlate with carfilzomib efficacy and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role as the primary metabolic pathway for paroxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking lornoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using lornoxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for cetirizine in a patient with a high-activity ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested weight loss target for a phentermine-treated patient based on their FTO genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for valproic acid in a patient with a known POLG1 mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the bioactivation of losartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT2B7 enzyme in the glucuronidation of diclofenac?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do PDCD1 genotypes correlate with pembrolizumab efficacy and toxicity phenotypes across different cancers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT2B7 genotypes correlate with valproic acid clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for acebutolol stratified by ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to axitinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvastatin in pediatric patients with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for fluvastatin adjusted for ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which MT-RNR1 variants are considered high-risk for aminoglycoside-induced ototoxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiovascular events for a CYP2C9 poor metabolizer taking celecoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for cardiovascular events in CYP2C9 poor metabolizers using celecoxib.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of nebivolol in patients with the ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should cabozantinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to ribostamycin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribostamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with ribostamycin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C19 enzyme in the metabolism of fluoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in the metabolic pathway of fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB1 gene product in the context of metoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB1's role as the beta-1 adrenergic receptor, the primary target for metoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with famotidine in individuals with MATE1 variants that reduce renal clearance?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sotalol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for sotalol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for flurbiprofen dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"flurbiprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for flurbiprofen therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolic clearance of nebivolol?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of vardenafil for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for kanamycin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"kanamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for kanamycin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the context of escitalopram therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 haplotypes correspond to aliskiren bioavailability phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of asthma-related death with long-acting beta-agonists like salmeterol in individuals homozygous for the Arg16 variant of ADRB2?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for lorlatinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2A6 enzyme in the metabolism of letrozole?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of atorvastatin for a patient with a DPYD poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of venetoclax for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do STAT1 genotypes correlate with interferon alfa efficacy and side effect phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended vortioxetine dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vortioxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nonconvulsive status epilepticus with cefepime in individuals with genetic variants affecting renal clearance or the blood-brain barrier?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended tramadol dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for tramadol in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism by which the ACE I/D polymorphism influences quinapril's effect?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sertraline dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for sertraline based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bisoprolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for bisoprolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should doxepin dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for doxepin in CYP2C19 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP2C9's role in rosuvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma concentrations of midostaurin's active metabolites (CGP62221 and CGP52421) in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma alfentanil concentrations in a CYP3A4 rapid metabolizer during surgery?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should omalizumab dosing be adjusted for a patient with a specific variant in the high-affinity IgE receptor (FCER1A) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do KCNH2 genotypes correlate with sotalol-induced cardiac arrhythmia phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP3A4 in the extensive first-pass metabolism of verapamil?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to tigecycline clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for liraglutide in type 2 diabetes or obesity based on GLP1R genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is primaquine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"primaquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for primaquine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does IFNL3 genotype influence the rapid virologic response (RVR) to peginterferon alfa-2b therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Pharmacodynamic data on RVR rates stratified by IFNL3 genotype for patients on peginterferon alfa-2b\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fexofenadine dosing be adjusted for a patient with a low-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of donepezil therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the DPYD gene in fluoropyrimidine metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"capecitabine\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Role of the DPYD enzyme in the catabolism of fluoropyrimidines\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for netilmicin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"netilmicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for netilmicin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment resistance to temozolomide in glioblastoma patients with a methylated MGMT promoter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What CYP4F2 genotype is associated with a need for a higher warfarin dose?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP4F2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Definition of the CYP4F2 genotype that requires increased warfarin dosage\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 gene product in the context of carvedilol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A4 genotypes map to lamotrigine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for propranolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for propranolol adjusted for ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma quinine concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for tamsulosin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should omeprazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pindolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for pindolol in patients of African ancestry, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing severe adverse effects to imatinib in individuals with the ABCG2 421C>A polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the DPYD enzyme inactivate fluorouracil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluorouracil\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Mechanism of action for DPYD enzyme in the inactivation of fluorouracil\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of UGT1A9 in the glucuronidation of fenofibrate's active metabolite?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking piroxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using piroxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sulfamethoxazole / trimethoprim in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfamethoxazole / trimethoprim\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for sulfamethoxazole / trimethoprim in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 variants and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the FCER1A receptor and how might its variants impact the pharmacodynamics of omalizumab?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atomoxetine starting dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atomoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf\", \"Content to Search\": \"Recommended starting dose and titration schedule for atomoxetine in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atorvastatin in pediatric patients with heterozygous DPYD variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma famotidine concentrations in a patient with a high-function MATE1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of CYP3A4 in the metabolism of fingolimod?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should morphine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for morphine based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of QTc prolongation with methadone in patients with reduced CYP2B6 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 rapid metabolizer for pantoprazole therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the extensive metabolism of lapatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using pindolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ertapenem in elderly patients with a genetic susceptibility to CNS toxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP1A2 genotypes map to anagrelide metabolism and efficacy phenotypes in essential thrombocythemia?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of leflunomide for a patient identified as a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which ACE genotypes are associated with poor response phenotypes to quinapril therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for maraviroc therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for labetalol in patients with heart failure and an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for labetalol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Angiotensin II Receptor Type 1 (AGTR1), the target of candesartan, and how do its variants alter drug affinity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of alfuzosin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of tacrolimus toxicity in patients with low-function POR variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the RYR1 gene in the mechanism of isoflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the RYR1 gene function and its role in the pathophysiology of isoflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2A6 enzyme in the 8-hydroxylation of efavirenz?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended tropisetron dose for a pregnant patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tropisetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Dosing guidance for tropisetron in pregnant CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLCO1B1 genotypes correlate with lopinavir clearance and efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific ondansetron dosing recommendations for pediatric CYP2D6 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ondansetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Pediatric dosing recommendations for ondansetron based on CYP2D6 ultrarapid metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for eltrombopag in ITP patients of East Asian ancestry, considering their higher prevalence of specific SLCO1B1 and ABCG2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperlipidemia with sirolimus in patients who are CYP3A5 non-expressers (*3/*3)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for acebutolol in patients with asthma and an ADRB2 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for acebutolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tramadol in pediatric patients post-tonsillectomy with an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for tramadol in pediatric post-tonsillectomy patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for levomilnacipran in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of lurasidone for a patient identified as a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of symptomatic hypotension with alfuzosin in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking duloxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking paroxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for treatment non-response in paroxetine users with the SLC6A4 s/s genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the basic mechanism by which MT-RNR1 variants increase susceptibility to the ototoxic effects of aminoglycosides?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the N-demethylation of imipramine to desipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Function of CYP2C19 in the metabolic conversion of imipramine to desipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"enflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding with rivaroxaban in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in ibuprofen exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on ibuprofen exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for milnacipran based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to abemaciclib clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of electrolyte imbalance with furosemide in patients with specific SLC12A1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of sotalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on sotalol effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma armodafinil concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma lovastatin concentrations in a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for lovastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should duloxetine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for duloxetine based on HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of pazopanib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to dacarbazine in melanoma patients with a methylated MGMT promoter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the MGMT enzyme in repairing DNA alkylation caused by lomustine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should midostaurin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ADD1 genotypes correlate with antihypertensive response phenotypes to HCTZ?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of 'wearing-off' phenomena with levodopa in individuals with the high-activity COMT 'Val' allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCB1 genotypes correlate with etoposide clearance and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MAOA genotypes correlate with the risk of tedizolid-induced adverse effects?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sulfadiazine contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadiazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sulfadiazine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A3 enzyme in the metabolic clearance of pitavastatin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the NAD(P)H Quinone Dehydrogenase 1 (NQO1) enzyme in the reductive activation of mitomycin C?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for lornoxicam dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for lornoxicam therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2D6 diplotypes are associated with increased tolterodine exposure phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested anti-Factor Xa activity level for a rivaroxaban-treated patient based on their ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCG2 genotypes correlate with febuxostat response and toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should praziquantel dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to everolimus clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma buprenorphine concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for buprenorphine in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using milnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvastatin in CYP3A5 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC47A1 genotypes correlate with famotidine elimination phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should voriconazole dosing be adjusted for a pediatric patient who is a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"voriconazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for voriconazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe hypertension and proteinuria with lenvatinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to hydroxyzine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT2B7 genotypes map to zidovudine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluvoxamine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dapsone contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dapsone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for dapsone in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nitrofurantoin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofurantoin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with nitrofurantoin use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nebivolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for nebivolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for labetalol in elderly patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for labetalol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma rosuvastatin concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for rosuvastatin in CYP2C9 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2C19's role in vilazodone metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should rivastigmine dosing be adjusted for a patient with a low-activity BCHE (butyrylcholinesterase) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of quetiapine for a patient identified as a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific thioguanine dosing recommendations for patients of East Asian ancestry due to higher prevalence of NUDT15 variants?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dosing guidance for thioguanine in East Asian populations considering NUDT15 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for isoflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for isoflurane in patients with RYR1-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 gene product in the context of atenolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofurantoin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target bronchodilator response for a salmeterol-treated patient based on their ADRB2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding and atrial fibrillation with ibrutinib in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking pitavastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should solifenacin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe nausea and vomiting with tigecycline in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a correlation between IFNL4 genotype and interferon-stimulated gene (ISG) expression levels before peginterferon alfa-2a treatment?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Pharmacodynamic data linking IFNL4 genotype to baseline ISG expression levels\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sulfanilamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfanilamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sulfanilamide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of CYP3A4 in the N-demethylation of diltiazem?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target levels of DNA methylation in tumor cells for a dacarbazine-treated patient based on their MGMT status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of maculopapular exanthema (MPE) for an HLA-A*31:01 carrier taking carbamazepine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for MPE in HLA-A*31:01 carriers using carbamazepine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic effect (e.g., change in blood pressure) for isosorbide dinitrate based on a patient's ALDH2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the pharmacokinetics of fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of ABCG2's role as an efflux transporter affecting fluvastatin disposition.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atenolol in patients with asthma and an ADRB2 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for atenolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for itraconazole therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for mometasone in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should the starting dose of methadone be adjusted for a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for methadone initiation in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for betaxolol stratified by ADRB1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP1A2 poor metabolizer for clozapine therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma rivastigmine concentrations in a patient with a specific BCHE genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target level of gastric acid suppression for a misoprostol-treated patient based on their PTGER3 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the N-dealkylation of alfentanil?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sunitinib in patients with renal cell carcinoma and known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to crizotinib clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tacrolimus dosing be adjusted for a patient with a POR*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of genital mycotic infections with dapagliflozin in individuals with specific UGT1A9 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should remifentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for remifentanil based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Torsades de Pointes with azithromycin in individuals with congenital long QT syndrome caused by KCNH2 mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in milnacipran metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do HCAR2 genotypes correlate with niacin's efficacy versus its flushing side effect?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for lovastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for lovastatin in CYP3A4 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for norverapamil in a patient with a CYP3A4 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the beta-2 adrenergic receptor (ADRB2) and how do its variants alter albuterol binding?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of emotional blunting with sertraline in OPRM1 G-allele carriers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of fluconazole for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of poor response to fexofenadine in individuals with high-function SLCO1B1 transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should interferon alfa dosing be adjusted for a patient with a specific variant in the STAT1 gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which dimercaprol causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dimercaprol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of dimercaprol-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of allopurinol for a patient with the ABCG2 Q141K variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of metabolic acidosis with topiramate in patients with specific CA2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering kanamycin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"kanamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for kanamycin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma pravastatin concentrations in an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for pravastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe neutropenia with gemcitabine in individuals with low-activity CDA variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma methadone concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for methadone in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for nifedipine in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to citalopram for individuals with the HTR2A rs7997012 A allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for altered citalopram efficacy in patients with the HTR2A rs7997012 A allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the IL-4 receptor alpha subunit (IL4R), the target of dupilumab, in mediating IL-4 and IL-13 signaling?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for alpha-hydroxymidazolam in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pegloticase in a patient with chronic gout and G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pegloticase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for pegloticase in G6PD deficient patients with chronic gout.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mercaptopurine dosing recommendation for a patient with Crohn's disease who is a TPMT intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dosing guidance for mercaptopurine in Crohn's disease patients with TPMT intermediate metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of transaminase elevation with remdesivir in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal side effects with cholestyramine in individuals with specific FXR variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested level of eosinophil depletion for a benralizumab-treated patient based on their IL5RA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma glipizide concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP1A2 genotypes are classified as poor metabolizers in the context of olanzapine treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should zolpidem dosing be adjusted for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C9 genotypes are classified as poor metabolizers in the context of naproxen treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HTR2A variants are associated with altered fluvoxamine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of HTR2A variants and their corresponding impact on fluvoxamine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should vortioxetine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vortioxetine based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vilazodone in a pediatric patient with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for vilazodone in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of stent thrombosis with prasugrel in patients with the PON1 192R allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma dolutegravir concentrations in a patient with a specific UGT1A1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for artemether-lumefantrine in pediatric malaria patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of toxicity in a CYP2D6 poor metabolizer taking imipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of toxicity in CYP2D6 poor metabolizers on imipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of diclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in diclofenac's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do TPMT genotypes correlate with cisplatin-induced hematologic toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to quinine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"quinine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after quinine administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of tenoxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in tenoxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for promethazine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do KCNH2 genotypes correlate with azithromycin-induced cardiac arrhythmia phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with standard pantoprazole dosing for a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pantoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using pantoprazole.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should acebutolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for acebutolol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in acebutolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ABCG2 genotypes correlate with dasatinib response phenotypes in chronic myeloid leukemia (CML)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a documented increased risk of adverse effects from desipramine in CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2C19 poor metabolizers using desipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced efficacy of ondansetron in individuals with high-activity ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with doxycycline in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for paromomycin in an individual with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paromomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Dosing recommendations or alternative therapies for paromomycin in patients with pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on heart failure outcomes with nadolol in patients with the GRK5 Leu41 variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific peginterferon alfa-2a treatment duration guidelines for African-American patients based on their IFNL4 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2a\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Treatment duration recommendations for peginterferon alfa-2a in African-American patients stratified by IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should aliskiren dosing be adjusted for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of gastrointestinal bleeding for naproxen users with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should sotalol dosing be adjusted for a patient with a specific KCNH2 (hERG) gene variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC12A3 genotypes correlate with antihypertensive response phenotypes to chlorthalidone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2D6 genotypes map to quinidine clearance phenotypes and its inhibition of P-glycoprotein?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of subtherapeutic posaconazole levels in individuals with high-activity UGT1A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sotalol in elderly patients with hypertension who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for sotalol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C19 enzyme in the bioactivation of clopidogrel?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clopidogrel\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf\", \"Content to Search\": \"Explanation of CYP2C19's function in converting clopidogrel to its active metabolite.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with eltrombopag in individuals with the SLCO1B1 c.521T>C polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the RET inhibitor selpercatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should nilotinib dosing be adjusted for a patient with a UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is high-dose vitamin C contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin c\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for high-dose vitamin C in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an increased risk of adverse events with piroxicam in patients with reduced-function CYP2C8 alleles?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using piroxicam.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of CYP2C9 in the metabolism of azilsartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of insomnia and confusion with selegiline in individuals with reduced CYP2B6 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of vilazodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the serotonin transporter's (SERT) role as a primary target of vilazodone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic trough concentration for cyclosporine in a CYP3A5 expresser versus a non-expresser?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C8 diplotypes define a normal metabolizer for the purposes of rosiglitazone therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does DPYD deficiency affect the pharmacokinetics of tegafur's active metabolite, 5-fluorouracil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tegafur\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Pharmacokinetic parameters of 5-fluorouracil in DPYD deficient individuals after tegafur administration\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SULT1A1 enzyme in the detoxification pathway of acetaminophen?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking pindolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for pindolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma simeprevir concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ripretinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of anticholinergic side effects in a CYP2C19 poor metabolizer taking clomipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Quantified risk of anticholinergic effects in CYP2C19 poor metabolizers on clomipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should atenolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for atenolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended maximum daily dose of acetaminophen for a patient with a UGT1A6*2/*2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma desacetyldiltiazem concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sildenafil for pulmonary hypertension in patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should infigratinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pravastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for pravastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended methadone dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for methadone in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolic pathway of risperidone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of reduced efficacy of granisetron in CYP2D6 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of sufentanil therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for sufentanil.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of omeprazole for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target INR range for a warfarin-treated patient with homozygous Factor V Leiden?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma N-acetylprocainamide (NAPA) in a NAT2 rapid acetylator?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes correspond to the CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2B6 poor metabolizer category.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ACHE genotypes correlate with donepezil efficacy phenotypes in Alzheimer's disease?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ALDH2 genotypes correlate with the hemodynamic response to isosorbide dinitrate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for posaconazole in a patient with a low-activity UGT1A4 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of naltrexone therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for naltrexone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for desipramine clearance involving the CYP2D6 enzyme?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Role of CYP2D6-mediated hydroxylation in desipramine metabolism\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for glipizide in a diabetic patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glipizide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for glipizide in G6PD deficient patients with type 2 diabetes.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of fentanyl therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for fentanyl.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of pemigatinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C8 enzyme in the metabolism of amiodarone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do PTGER3 genotypes correlate with the uterotonic effects of misoprostol?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for carvedilol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is moxifloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"moxifloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for moxifloxacin in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of phenytoin for a patient with the ABCB1 3435C>T variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which linezolid impacts mitochondrial protein synthesis, leading to potential toxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the AOX1 enzyme in the primary metabolic pathway of zaleplon?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target minimum inhibitory concentration (MIC) for levofloxacin based on the gyrA/parC genotype of the infecting organism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is glipizide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glipizide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for glipizide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered levomethadone response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on levomethadone response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered oxycodone response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on oxycodone response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should duloxetine dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration ranges for desloratadine in a patient with a specific ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of pulmonary fibrosis with bleomycin in individuals with low-activity BLMH variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A4 enzyme in the glucuronidation of lamotrigine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of doxorubicin for a patient with a SLC22A16 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should bisoprolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for bisoprolol based on GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the SVR probability for a peginterferon/ribavirin regimen in a patient with the unfavorable IFNL4-ΔG allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Quantified SVR rates for combination therapy with ribavirin in patients with the unfavorable IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK4 gene product in the context of betaxolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for isoniazid in a patient with a NAT2 intermediate acetylator genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for ibuprofen recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for ibuprofen based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of RANKL, the target of denosumab, in osteoclast differentiation and function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tepotinib in METex14 skipping lung cancer patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with zafirlukast in patients with CYP2C9*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for tenoxicam dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tenoxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for tenoxicam therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should erythromycin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma duloxetine concentrations in a CYP1A2 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of sedation for olanzapine users with decreased CYP1A2 activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of dabigatran for a patient with a high-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of the pan-BCR-ABL inhibitor ponatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of carmustine (BCNU) for a patient with a GSTP1 Ile105Val polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A4's role in pitavastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do bacterial PBP genotypes correlate with cefuroxime resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atomoxetine dose for a child weighing over 70kg who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atomoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf\", \"Content to Search\": \"Specific dosing guidance for atomoxetine in pediatric patients >70kg with CYP2D6 poor metabolizer status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do proteasome subunit genotypes correlate with bortezomib resistance phenotypes in multiple myeloma?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should simeprevir dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydrocodone in pediatric patients with a COMT high-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidelines for hydrocodone adjusted for COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the serotonin transporter's (SERT) role as a primary target of venlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sulfisoxazole in a pediatric patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfisoxazole\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for sulfisoxazole in G6PD deficient children.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected area under the curve (AUC) for pantoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pantoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on pantoprazole exposure in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for montelukast in asthmatic children with the CYP2C8*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which trametinib causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trametinib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of trametinib-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma atorvastatin concentrations in an individual with SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for atorvastatin in individuals with SLCO1B1 intermediate function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake and clearance of fexofenadine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the NAT2 enzyme in the metabolism of procainamide to its active metabolite, NAPA?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended duloxetine dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol or alternative medication recommendation for duloxetine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does peginterferon alfa-2b's mechanism of action interact with the IFNL3-mediated immune pathway?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Interaction between peginterferon alfa-2b's antiviral effect and the IFNL3 signaling pathway\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is tolbutamide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolbutamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for tolbutamide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rivaroxaban in elderly patients with renal impairment and a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor weight loss response to orlistat in individuals with PNLIP variants that are resistant to inhibition?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma galantamine concentrations in a CYP2D6 ultrarapid metabolizer who is also a CYP3A4 normal metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which glyburide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"glyburide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of glyburide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking lovastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk data for SAMS in CYP3A4 poor metabolizers using lovastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target for sweat chloride concentration reduction with ivacaftor therapy in responsive CFTR genotypes?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ivacaftor\", \"Gene Name\": \"CFTR\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf\", \"Content to Search\": \"Pharmacodynamic data on expected sweat chloride reduction following ivacaftor treatment.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for colchicine in patients with renal impairment and a known CYP3A4 poor metabolizer genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"diclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C19 genotypes map to lansoprazole efficacy phenotypes for erosive esophagitis?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C9 genotypes are classified as poor metabolizers in the context of leflunomide treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the ABCG2 decreased function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of elevated creatine phosphokinase (CPK) with daptomycin in individuals with underlying muscular dystrophy gene mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for desvenlafaxine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which genotypes are associated with the DPYD intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluorouracil\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the DPYD intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methylene blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on reduced efficacy of nadolol in patients with the ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of Clostridium difficile infection with pantoprazole in CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the specific biochemical reaction catalyzed by NUDT15 that deactivates thioguanine's active metabolites?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"NUDT15\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Mechanism of NUDT15 enzyme in hydrolyzing active thioguanine metabolites\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolic clearance of irbesartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended esomeprazole dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esomeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for esomeprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors correlate with the conversion rate of lisdexamfetamine to dextroamphetamine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of olanzapine for a patient identified as a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Monoamine Oxidase A (MAOA) enzyme in the metabolism of sumatriptan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose adjustment for citalopram based on ABCB1 transporter genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended vilazodone dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vilazodone\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for vilazodone in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should zidovudine (AZT) dosing be adjusted for a patient with a UGT2B7*2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of poor response to thalidomide in multiple myeloma patients with low-expression CRBN variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HTR2A variants are associated with altered duloxetine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of HTR2A variants and their corresponding impact on duloxetine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which genotypes correspond to the CYP2C19 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Genotype or diplotype definitions for the CYP2C19 intermediate metabolizer phenotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the pharmacokinetics of atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of ABCG2's role as an efflux transporter affecting atorvastatin disposition.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should paroxetine dosing be adjusted for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for paroxetine in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to fluoxetine in a patient with the HTR2A rs7997012 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for fluoxetine stratified by HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the mechanism of action of milnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for milnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for theophylline in a patient with a CYP1A2 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CACNA1S gene in the mechanism of succinylcholine-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"succinylcholine\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the CACNA1S gene function and its role in the pathophysiology of succinylcholine-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for streptomycin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"streptomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for streptomycin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the N-dealkylation of buprenorphine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected area under the curve (AUC) for omeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"omeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on omeprazole exposure in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"toluidine blue\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do HCAR2 genotypes correlate with dimethyl fumarate tolerability phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of clonazepam for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of atorvastatin for a patient who is a UGT1A1 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should edoxaban dosing be adjusted for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking sertraline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sertraline\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data (e.g., remission rates) for sertraline based on HTR2A rs6313 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to nicorandil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nicorandil\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after nicorandil administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should valproic acid dosing be adjusted for a patient with a UGT2B7*2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as blood pressure changes, for metoprolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended lovastatin dose for an individual with SLCO1B1 low function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for lovastatin in individuals with SLCO1B1 low function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of ertapenem for a patient with a genetic predisposition to seizures?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do RRM1 genotypes correlate with hydroxyurea efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A4's role in atorvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding function scores for the SLCO1B1 intermediate function phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations regarding phenytoin use and HLA-B*15:02 testing in certain ethnic populations?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Recommendations for HLA-B*15:02 screening in specific populations before phenytoin initiation\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for tafenoquine for malaria prophylaxis in a G6PD deficient child?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tafenoquine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for tafenoquine in G6PD deficient children for malaria prophylaxis.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for bisoprolol in patients with asthma and an ADRB2 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for bisoprolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the P-glycoprotein (encoded by ABCB1) in the distribution of citalopram?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended rabeprazole dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rabeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for rabeprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target urinary glucose excretion for a dapagliflozin-treated patient based on their UGT1A9 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sulfamethoxazole / trimethoprim contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfamethoxazole / trimethoprim\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sulfamethoxazole / trimethoprim in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should glipizide dosing be adjusted for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for simvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for simvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hepatotoxicity with diclofenac in individuals with low-activity UGT2B7 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ruxolitinib in myelofibrosis patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the context of fluvoxamine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of fluvoxamine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"indomethacin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluvoxamine in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected increase in aceclofenac exposure (AUC) in a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on aceclofenac exposure in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dibekacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "In which ethnic populations is the HLA-B*58:01 allele most prevalent, necessitating pre-screening for allopurinol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"allopurinol\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf\", \"Content to Search\": \"Information on ethnic populations with high prevalence of the HLA-B*58:01 allele\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do bacterial gyrA and parC genotypes correlate with levofloxacin resistance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for netilmicin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"netilmicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for netilmicin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for halothane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for halothane in the context of CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for sufentanil in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of P-glycoprotein (ABCB1) in limiting loratadine's CNS penetration?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of propranolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to propranolol therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which TPMT diplotypes define a normal metabolizer for the purpose of propranolol therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of aceclofenac?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aceclofenac\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on aceclofenac exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfadimidine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadimidine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sulfadimidine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pindolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for pindolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for venlafaxine in an elderly patient with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for venlafaxine in elderly CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should escitalopram dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for escitalopram based on HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for solifenacin in patients with renal impairment and a known CYP3A4 variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should codeine dosing be adjusted for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for 5-hydroxymethyltolterodine (the active metabolite) in a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for metoprolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for metoprolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'low-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to citalopram in a patient with the HTR2A rs7997012 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for citalopram stratified by HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking rosuvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the IFNL4-ΔG variant, which produces a disruptive protein, affect the antiviral activity of ribavirin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Interaction between the IFNL4-ΔG gene product and the mechanism of action of ribavirin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of calcium carbonate for a patient with a specific variant in the calcium-sensing receptor (CASR) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of nadolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on nadolol effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of CNS adverse effects with ertapenem in individuals with genetic variants affecting GABAergic pathways?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the suggested plasma concentration limits for tedizolid to avoid hematologic toxicity based on MAOA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the MRP2 transporter (encoded by ABCC2) in the renal tubular secretion of tenofovir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended ivacaftor dose for a patient with the CFTR G551D mutation?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ivacaftor\", \"Gene Name\": \"CFTR\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf\", \"Content to Search\": \"Recommended ivacaftor dosage for patients with the CFTR G551D genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should alfentanil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of rituximab for a patient with a specific FCGR3A (Fc gamma receptor IIIa) V158F polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do COMT genotypes correlate with cisplatin-induced neurotoxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of verapamil for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for using topical sulfanilamide in a G6PD deficient patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfanilamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for topical sulfanilamide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma indomethacin concentrations in a patient with a high-activity UGT2B7 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of SLCO1B1's role as a hepatic uptake transporter affecting rosuvastatin clearance.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for cabozantinib in renal cell carcinoma patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should indomethacin dosing be adjusted for a patient with a UGT2B7*2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SLC22A2 genotypes map to dalfampridine clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding with dabigatran in individuals with low-function ABCB1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dabrafenib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dabrafenib\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with dabrafenib use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to vitamin K?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin k\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after vitamin K administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of canagliflozin for a patient with a UGT1A9*3 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations of N-desmethylenzalutamide (active metabolite) in a patient who is a CYP2C8 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for fluoxetine based on a patient's HTR2C genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the pharmacokinetics of pitavastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of ABCG2's role as an efflux transporter affecting pitavastatin disposition.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the glucuronidation of telmisartan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nebivolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nebivolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should labetalol dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for labetalol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for zolpidem in female patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nicorandil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nicorandil\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with nicorandil use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended lovastatin dose for a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for lovastatin in CYP3A5 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HCAR2 receptor in mediating both the therapeutic and adverse effects of niacin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 gene product in the context of bisoprolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nephrotoxicity with cyclosporine in patients who are CYP3A5 non-expressers (*3/*3)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe diarrhea and liver enzyme elevation with bosutinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sotalol dose for an individual with a GRK4 variant associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for sotalol based on GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of gentamicin for a patient with a specific variant in a mitochondrial rRNA gene (e.g., MT-RNR1)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in converting venlafaxine to its active metabolite, O-desmethylvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma rosuvastatin concentrations in an individual with SLCO1B1 intermediate function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"SLCO1B1\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for rosuvastatin in individuals with SLCO1B1 intermediate function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfadiazine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadiazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sulfadiazine use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C9 genotypes map to vismodegib metabolism phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the pharmacokinetics of pravastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of ABCG2's role as an efflux transporter affecting pravastatin disposition.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pravastatin dose for an individual with an HMGCR variant associated with reduced statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pravastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pravastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dose adjustment for lansoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lansoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidance for lansoprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a UGT1A1 intermediate metabolizer for irinotecan therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin c\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of palmar-plantar erythrodysesthesia with ripretinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for oral semaglutide in patients with a genotype known to affect absorption?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking codeine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of codeine in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target intracellular tenofovir diphosphate concentrations in a patient with a specific ABCC2 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects from celecoxib in individuals with a CYP2D6 gene duplication?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target LDL reduction for an ezetimibe-treated patient based on their NPC1L1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenazopyridine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of next-day impairment with zolpidem in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for sotalol in patients with asthma and the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for sotalol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for bisoprolol in patients with heart failure and a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for bisoprolol in heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for intravenous vitamin C administration in a G6PD deficient patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin c\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for IV vitamin C use in G6PD deficient patients, particularly in the context of sepsis or cancer therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should spironolactone dosing be adjusted for a patient with a CYP3A4 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of a disulfiram-like reaction with metronidazole and alcohol in individuals with CYP2C9 poor metabolizer status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of fluoxetine for a patient with a BDNF Val66Met polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of meloxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"meloxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in meloxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should betaxolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for betaxolol based on ADRB1 Arg389Gly genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of warfarin for a patient with the APOE E4 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing adjustment for amitriptyline in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol for amitriptyline in CYP2C19 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should loperamide dosing be adjusted for a patient with a low-function ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma atorvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for atorvastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the COMT enzyme in the pharmacological response to oxycodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Mechanism of interaction between COMT enzyme activity and oxycodone's effects.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for codeine in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing recommendations or contraindications for codeine in lactating mothers with a CYP2D6 UM phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of nitroglycerin for a patient with an ALDH2*2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CES1 genotype correlate with the hydrolysis of oseltamivir to its active form?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should hydroxyzine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should fluoxetine dosing be adjusted for an individual with the SLC6A4 L/L genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing or therapeutic recommendations for fluoxetine based on SLC6A4 5-HTTLPR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking rosuvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pharmacodynamic data (LDL-C reduction) for rosuvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for milnacipran in a pediatric patient with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for milnacipran in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of fluvoxamine in a CYP2B6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for fluvoxamine in CYP2B6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of doxepin for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxepin\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Recommended starting dose for doxepin in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in betaxolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dimercaprol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of remifentanil therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for remifentanil.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of gastrointestinal side effects with metformin in individuals with specific SLC22A1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of morphine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for morphine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should pembrolizumab dosing be adjusted for a patient with a specific PD-1 (PDCD1) gene polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OPRM1 gene product in the context of methadone therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Explanation of OPRM1's role as the mu-opioid receptor, the primary target for methadone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of morphine toxicity for a CYP2D6 ultrarapid metabolizer taking codeine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk, incidence rate, or odds ratio for morphine toxicity in CYP2D6 UMs using codeine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of bismuth subsalicylate for a patient with a specific genetic variant affecting salicylate metabolism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which moxifloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"moxifloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of moxifloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking atenolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended levomilnacipran dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for levomilnacipran in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma quinidine concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do KCNJ11 genotypes correlate with glimepiride efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for alectinib in ALK-positive lung cancer patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for betaxolol in elderly patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for betaxolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested anti-Factor Xa activity level for a fondaparinux-treated patient based on their SERPINC1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of nabumetone's active metabolite?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nabumetone\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in the metabolic pathway of nabumetone's active metabolite.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tolazamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolazamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with tolazamide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of FDPS in the mevalonate pathway, which is inhibited by zoledronic acid?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for methoxyflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methoxyflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for methoxyflurane in the context of CACNA1S-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2D6 enzyme in the metabolic clearance of mexiletine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of neurotoxicity with altretamine in individuals with reduced CYP1A2 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of UGT2B7-mediated glucuronidation in the elimination of indomethacin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C9 diplotypes define a normal metabolizer for the purposes of azilsartan therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma nilotinib concentrations in a patient with a specific UGT1A1 diplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for lornoxicam use in elderly patients who are also CYP2C9 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lornoxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dosing guidance for lornoxicam in elderly CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of dolutegravir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HMGCR variants are associated with altered statin response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Definitions of HMGCR variants or genotypes associated with altered statin efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended propranolol dose for an individual with the GRK5 Gln41Leu polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for propranolol based on GRK5 Gln41Leu genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of trimipramine for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Recommended starting dose for trimipramine in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the PD-L1 ligand and its interaction with the PD-1 receptor, which is blocked by nivolumab?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A9 enzyme in the metabolism of sorafenib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should alectinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for desethylchloroquine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma eltrombopag concentrations in a patient with a high-function SLCO1B1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended venlafaxine dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for venlafaxine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma valproic acid concentrations in a patient with a high-activity UGT2B7 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma vincristine concentrations in a CYP3A5 expresser versus a non-expresser?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK5 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvoxamine in adolescents with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for fluvoxamine in adolescent patients, adjusted for SLC6A4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of sedation and hypotension with guanfacine in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommendation for using topical nitrofural in a G6PD deficient patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofural\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Guidelines for topical nitrofural use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to temsirolimus conversion and clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of tigecycline for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended omeprazole dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"omeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for omeprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma tepotinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma SN-38 (irinotecan's active metabolite) in a UGT1A1 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should alfentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for alfentanil based on OPRM1 variants affecting receptor function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HCAR2 receptor in mediating the flushing side effect of dimethyl fumarate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for doxorubicin in a pediatric cancer patient with G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxorubicin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Pediatric-specific dosing guidelines for doxorubicin in G6PD deficient children undergoing chemotherapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for aripiprazole in children with a CYP2D6 gene duplication?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for gabapentin in a patient with a high-function SLC22A2 transporter?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target reduction in Eczema Area and Severity Index (EASI) score for a dupilumab-treated patient based on their IL4R genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of nifedipine for a patient identified as a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should irbesartan dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is doxorubicin contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"doxorubicin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for doxorubicin in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which CYP2C9 genotypes are classified as intermediate metabolizers in the context of ketorolac treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cardiovascular events with rosiglitazone in CYP2C8 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of vortioxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in vortioxetine metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aspirin dosing?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"aspirin\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Guidance on combined CYP2C8/CYP2C9 genotypes for aspirin therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HLA-A gene in the immune response related to drug hypersensitivity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Basic function of the HLA-A gene and its role in antigen presentation leading to drug hypersensitivity\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of non-response to lithium in individuals with specific GADL1 polymorphisms?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypoglycemia with repaglinide in individuals with low-function SLCO1B1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do SULT1A1 genotypes map to acetaminophen sulfation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which sulfasalazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfasalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of sulfasalazine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of bleeding complications with warfarin in individuals carrying the APOE E2 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for clarithromycin in patients with known CYP3A4 variants who are also taking other CYP3A4 substrates?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for rasburicase for tumor lysis syndrome in a G6PD deficient cancer patient?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rasburicase\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for rasburicase in G6PD deficient patients with tumor lysis syndrome.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for citalopram in adolescents with the HTR2A rs7997012 A/A genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing guidelines for citalopram in adolescent patients, adjusted for HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma fentanyl concentrations in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for fentanyl stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should amlodipine dosing be adjusted for a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for venlafaxine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for venlafaxine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do BDNF genotypes correlate with fluoxetine efficacy phenotypes in major depressive disorder?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of hydroxyurea for a patient with a specific variant in a ribonucleotide reductase (RRM1) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for neomycin in a pediatric patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"neomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Specific dosing guidance for neomycin in pediatric populations carrying pathogenic MT-RNR1 variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of digoxin toxicity in patients with the ABCB1 3435C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for labetalol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of atenolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the beta-2 adrenergic receptor and its interaction with atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do BLMH genotypes correlate with bleomycin-induced lung toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic serum lithium level for a patient based on their GADL1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for ciprofloxacin in a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ciprofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for ciprofloxacin in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for methadone in children with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for methadone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended clomipramine dose for a patient who is a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clomipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing recommendation for clomipramine in CYP2D6 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should valsartan dosing be adjusted for a patient with a SLCO1B1 low-function genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended oxycodone dose for an individual with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for oxycodone in individuals with a COMT low-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking sufentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for sufentanil in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pantoprazole dose for a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pantoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for pantoprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of sucralfate for a patient with a genetic predisposition to aluminum toxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of pomalidomide for a patient with a specific variant in the CRBN (cereblon) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of clindamycin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected plasma concentration (AUC) of atomoxetine in a CYP2D6 poor metabolizer compared to a normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atomoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf\", \"Content to Search\": \"Pharmacokinetic data, specifically area under the curve (AUC) values, for atomoxetine in CYP2D6 poor vs. normal metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of azilsartan for a patient who is a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer for zafirlukast therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of alfuzosin for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of oxymorphone in a CYP2D6 poor metabolizer after a standard dose of oxycodone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration data for oxymorphone (the active metabolite of oxycodone) in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is a dose adjustment for piroxicam recommended based on CYP2C8 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for piroxicam based on CYP2C8 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should proguanil dosing be adjusted for a patient who is a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of cefuroxime for a patient with a specific variant in a penicillin-binding protein (PBP) gene of the infecting bacteria?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected impact on bilirubin concentrations in a UGT1A1 poor metabolizer treated with atazanavir?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atazanavir\", \"Gene Name\": \"UGT1A1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf\", \"Content to Search\": \"Expected bilirubin concentration levels or changes in UGT1A1 poor metabolizers on atazanavir therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should clopidogrel dosing be adjusted for a patient with the CES1 G143E variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for donepezil in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the beta-2 adrenergic receptor (ADRB2) and how do its variants alter carvedilol's effects?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of nephrotoxicity with piperacillin-tazobactam in individuals with low-function OAT transporter variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"quinine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of guanfacine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should erlotinib dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of life-threatening toxicity when administering tegafur to a DPYD poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tegafur\", \"Gene Name\": \"DPYD\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf\", \"Content to Search\": \"Quantified risk data or incidence rates of severe toxicity in DPYD poor metabolizers using tegafur\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ritalinic acid in a patient with a low-activity CES1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the OAT1 transporter in the uricosuric action of probenecid?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism of cross-reactivity between carbamazepine and oxcarbazepine in HLA-B*15:02 positive individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Mechanism of immunological cross-reactivity for carbamazepine and oxcarbazepine in HLA-B*15:02 carriers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of treatment failure with fosfomycin in infections caused by bacteria with MurA mutations?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of celecoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in celecoxib's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for atorvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for atorvastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Cereblon (CRBN) as the primary target of thalidomide and its role in protein degradation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there an established therapeutic window for phenytoin that differs based on HLA-B genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Information on whether HLA-B genotype affects the therapeutic range of phenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to dapsone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dapsone\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after dapsone administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for haloperidol in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRB2 gene product in the context of pindolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to pindolol therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which vitamin K causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vitamin k\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of vitamin K-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there any special considerations for using nortriptyline for smoking cessation in patients with known CYP2C19 variants?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Dosing or safety considerations for nortriptyline in smoking cessation related to CYP2C19 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended starting dose of donepezil for a patient identified as a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolazamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Description of CYP2D6's role in nadolol metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dosing for halothane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"halothane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Dosing protocol or avoidance recommendation for halothane in patients with CACNA1S-Malignant Hyperthermia Susceptibility.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking carvedilol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data (heart rate, blood pressure response) for carvedilol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma milnacipran concentrations in a CYP2C19 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges for milnacipran in CYP2C19 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should clopidogrel dosing be adjusted based on PON1 Q192R genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of lenvatinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma remifentanil concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for remifentanil in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2C8*3 allele affect the pharmacokinetics of celecoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Pharmacokinetic data on celecoxib exposure related to the CYP2C8*3 allele.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma morphine concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for morphine in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Allele function table or definitions for CYP2C8.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Does CYP2C19 genotype significantly alter the plasma concentrations of desipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pharmacokinetic data on the impact of CYP2C19 genotype on desipramine plasma levels\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using sotalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma atorvastatin concentrations in a CYP3A4 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for atorvastatin in CYP3A4 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested target HbA1c for a metformin-treated patient based on their ATM genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 polymorphism affect the first-pass metabolism of pantoprazole?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pantoprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Description of CYP2C19's role in pantoprazole's mechanism and metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for paroxetine in an adolescent with the HTR2A rs6313 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paroxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for paroxetine in adolescents based on HTR2A genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hallucinations with dextromethorphan in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking gliclazide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gliclazide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with gliclazide use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'normal-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for rosuvastatin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of levomilnacipran?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2D6's role in the metabolic pathway of levomilnacipran.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do AOX1 genotypes correlate with zaleplon clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking remifentanil?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using remifentanil.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should pazopanib dosing be adjusted for a patient with a UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended pitavastatin dose for an individual with ABCG2 decreased function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pitavastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for pitavastatin in individuals with ABCG2 decreased function.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of adverse effects to citalopram for individuals with the SLC6A4 S/S genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for increased adverse effects of citalopram in patients with the SLC6A4 S/S genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should atenolol dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for atenolol in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carbamazepine in a patient positive for the HLA-A*31:01 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Clinical dosing recommendation for carbamazepine in HLA-A*31:01 positive individuals\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking fluoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2B6 poor metabolizers using fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the ACE I/D polymorphism correlate with benazepril antihypertensive efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is sulfadimidine (sulfamethazine) contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfadimidine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for sulfadimidine in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of cisplatin-induced hearing loss in individuals with the low-activity COMT 'Met' allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the ABCB1 genotype correspond to simvastatin bioavailability phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the relative chance of achieving SVR with peginterferon alfa-2b for a patient with IFNL3 rs12979860 CC versus CT/TT genotypes?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL3\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Odds ratio or comparative SVR rates for peginterferon alfa-2b based on IFNL3 rs12979860 genotypes\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do host genetic factors (e.g., in carnitine metabolism) correlate with daptomycin-induced muscle toxicity phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"codeine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Diplotype definitions and corresponding activity scores for the CYP2D6 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of duloxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of SLC6A4's role as the serotonin transporter, a primary target of duloxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluoxetine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of fluoxetine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do MAOA genotypes correlate with sumatriptan efficacy phenotypes for migraine treatment?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of CNS side effects from gabapentin in individuals with specific SLC22A2 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma paroxetine concentrations based on COMT genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for vortioxetine in an elderly patient with a CYP2C19 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dosing adjustments for vortioxetine in elderly CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma rosuvastatin concentrations in a CYP3A4 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A4\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for rosuvastatin in CYP3A4 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"HMGCR\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pharmacodynamic data (LDL-C reduction) for fluvastatin based on HMGCR genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended alternative therapy to tamoxifen for a CYP2D6 poor metabolizer with breast cancer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tamoxifen\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf\", \"Content to Search\": \"Alternative therapy recommendations for tamoxifen in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for nebivolol stratified by ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of pravastatin for a patient with a UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of fenofibrate for a patient with a UGT1A9 promoter polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do IL5RA genotypes correlate with benralizumab-mediated antibody-dependent cell-mediated cytotoxicity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ADRB2 genotypes define response phenotypes to long-term salmeterol therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the contribution of CYP2C8 to the overall clearance of celecoxib?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"celecoxib\", \"Gene Name\": \"CYP2C8\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C8's role in celecoxib's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target trough concentrations for eszopiclone in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for donepezil in elderly patients with dementia and a CYP2D6 gene duplication?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ibrutinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of CYP2D6 in the O-demethylation of dextromethorphan to dextrorphan?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic response metric for cisplatin based on the tumor's ERCC1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a quantified risk of subtherapeutic INR associated with the CYP4F2*3 variant in patients taking warfarin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"warfarin\", \"Gene Name\": \"CYP4F2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf\", \"Content to Search\": \"Risk data for achieving subtherapeutic INR in patients with the CYP4F2*3 variant\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for pantoprazole in pediatric GERD patients with the CYP2C19*17 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested serum bicarbonate level to monitor in a topiramate-treated patient based on their CA2 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes for CYP2B6 define a poor metabolizer in the context of nevirapine therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 intermediate metabolizer for methadone therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of stent thrombosis with clopidogrel in patients with the PON1 192R allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a NAT2 slow acetylator for hydralazine therapy according to CPIC?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does MGMT promoter methylation status correlate with temozolomide efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes map to clarithromycin clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of serotonin syndrome when tedizolid is co-administered with an SSRI in a patient with a low-activity MAOA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 genotypes are associated with enhanced beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of methadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in methadone metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking naltrexone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for naltrexone in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of altretamine for a patient who is a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfacetamide?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfacetamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after sulfacetamide administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 enzyme in the context of pindolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"pindolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on pindolol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended ivacaftor dose for a pediatric patient aged 6-11 with a responsive CFTR genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ivacaftor\", \"Gene Name\": \"CFTR\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf\", \"Content to Search\": \"Pediatric dosing protocol for ivacaftor in children aged 6 to 11 years.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the viral neuraminidase enzyme and how do its genetic alterations confer resistance to zanamivir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ERCC1 enzyme in repairing cisplatin-induced DNA adducts?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data for bisoprolol stratified by GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma alfentanil concentrations in a CYP2D6 intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Plasma concentration ranges for alfentanil in CYP2D6 intermediate metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nebivolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nebivolol in patients of African ancestry, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering gentamicin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gentamicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for gentamicin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on heart failure outcomes with propranolol in patients with the GRK5 Leu41 variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of developing severe adverse effects to dasatinib in individuals with the ABCG2 421C>A polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'normal-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxycodone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for ranitidine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 poor metabolizer for dextromethorphan antitussive therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended nadolol dose for an individual with the ADRA2C Ins/Del polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for nadolol based on ADRA2C Ins/Del polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for propranolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for propranolol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is dose adjustment for rabeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rabeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Pediatric dosing guidance for rabeprazole in CYP2C19 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of artemether-lumefantrine for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of malignant hyperthermia when administering isoflurane to a patient with a pathogenic CACNA1S variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"isoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Incidence rates or risk data for isoflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered hydrocodone response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on hydrocodone response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of drug interactions (e.g., with theophylline) when ciprofloxacin is used by a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the Farnesoid X receptor (FXR) in bile acid homeostasis and its relation to cholestyramine's mechanism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C9 poor metabolizer for glipizide therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for carvedilol in elderly patients with a CYP2D6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carvedilol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing adjustments for carvedilol in elderly CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of altered linagliptin exposure in patients with the ABCB1 3435C>T polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Carboxylesterase 1 (CES1) in the metabolic pathway of methylphenidate?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for metoprolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for metoprolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of Carboxylesterase 1 (CES1) in the bioactivation of the prodrug oseltamivir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma rosuvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"rosuvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for rosuvastatin in CYP3A5 normal metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended citalopram dose for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"citalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for citalopram in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended fluvoxamine dose for a CYP2B6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvoxamine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Dose adjustment protocol for fluvoxamine in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the amitriptyline dosing recommendation for an elderly patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Geriatric dosing recommendations for amitriptyline in CYP2D6 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking methadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"methadone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using methadone.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested target for glucose reduction in a glimepiride-treated patient based on their KCNJ11 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking metoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"metoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as changes in ejection fraction, for metoprolol stratified by GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which MT-RNR1 variants increase susceptibility to kanamycin-induced ototoxicity?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"kanamycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Functional explanation of how MT-RNR1 variants interact with kanamycin to cause cellular damage.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for nebivolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for nebivolol in asthmatic patients, adjusted for ADRB2 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should naltrexone dosing be adjusted for a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"naltrexone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dose adjustment protocol for naltrexone in CYP2D6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should tobramycin dosing be adjusted for a patient with the MT-RNR1 m.1555A>G mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What GRK4 polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of GRK4 variants and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking labetalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking labetalol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of ototoxicity when administering plazomicin to a patient with a pathogenic MT-RNR1 variant?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"plazomicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for plazomicin-induced ototoxicity in MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for transdermal fentanyl in cancer patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolic pathway of celecoxib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"clopidogrel\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C19 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the HTR2A gene product in the context of fluoxetine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluoxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of fluoxetine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of QTc prolongation with tolterodine in CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2B6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"vortioxetine\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of morphine?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma cabozantinib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do ADRB2 genotypes correlate with carvedilol response phenotypes in heart failure?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for norbuprenorphine in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the MTHFR enzyme in folate metabolism and its impact on the action of the antifolate drug pemetrexed?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 genotypes are associated with enhanced beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"esmolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target free-phenytoin concentrations in a patient with a specific ABCB1 haplotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for labetalol in patients with heart failure and a GRK5 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for labetalol in heart failure patients, adjusted for GRK5 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do KRAS mutational statuses (wild-type vs. mutant) correlate with cetuximab efficacy phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for gefitinib in a patient with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for propranolol in pediatric patients with heterozygous TPMT variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of enasidenib for a patient with a UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for tigecycline in a patient with a CYP3A4 rapid metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target urinary concentrations for nitrofurantoin based on the NfsA/NfsB genotype of the infecting E. coli?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRB1 genotypes are associated with enhanced beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking escitalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should cyclosporine dosing be adjusted for a CYP3A5 expresser (*1/*1 or *1/*3)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered tramadol response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on tramadol response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the SLC6A4 gene product in the mechanism of action of desvenlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"desvenlafaxine\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Explanation of SLC6A4's role as the serotonin transporter, a primary target of desvenlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should metformin dosing be adjusted for a patient with a MATE1 (SLC47A1) variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma concentrations of duloxetine in a CYP2C19 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Plasma concentration ranges or AUC data for duloxetine in CYP2C19 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of statin-associated musculoskeletal symptoms (SAMS) for an individual with ABCG2 decreased function taking atorvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"ABCG2\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking atorvastatin.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for dibekacin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dibekacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for dibekacin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of chlorthalidone for a patient with a specific variant in the SLC12A3 (NCC) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of interleukin-2 (IL-2) for a patient with a specific variant in the IL2RA (CD25) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered remifentanil response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"remifentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on remifentanil response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A5 enzyme in the metabolism of fluvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP3A5's role in fluvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of trimipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"trimipramine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Role of CYP2D6 in the metabolic clearance of trimipramine\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of edema and fluid retention with pioglitazone in individuals with CYP2C8*3 alleles?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'high-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for atorvastatin lactone in a patient with a UGT1A1*28 allele?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydralazine in heart failure patients based on their NAT2 acetylator status?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma O-desmethyltramadol concentrations (from tramadol) in a patient with an OPRM1 variant leading to increased receptor expression?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values for O-desmethyltramadol (active metabolite of tramadol) stratified by OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CACNA1S gene in the mechanism of sevoflurane-triggered malignant hyperthermia?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"CACNA1S\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Explanation of the CACNA1S gene function and its role in the pathophysiology of sevoflurane-induced malignant hyperthermia.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2A6 genotypes map to letrozole clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2D6 normal metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma maraviroc concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is nitrofural (nitrofurazone) contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nitrofural\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for nitrofural in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfamethoxazole / trimethoprim?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfamethoxazole / trimethoprim\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with sulfamethoxazole / trimethoprim use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of sumatriptan for a patient with a MAOA uVNTR polymorphism associated with low activity?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended therapeutic range for lisinoprilat based on a patient's ACE genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2B6 enzyme in the metabolism of escitalopram?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Description of CYP2B6's role in the metabolic pathway of escitalopram.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for mesalazine in a patient with inflammatory bowel disease and G6PD deficiency?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mesalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing guidelines for mesalazine in G6PD deficient patients with IBD.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of propranolol in patients with the ADRB2 Gln27Glu polymorphism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP2C8 poor metabolizer for pioglitazone therapy according to CPIC guidelines?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP3A4 genotypes correlate with solifenacin efficacy phenotypes for overactive bladder?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway for atomoxetine, and what is the role of the CYP2D6 enzyme?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atomoxetine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf\", \"Content to Search\": \"Description of atomoxetine metabolism and the specific function of the CYP2D6 enzyme in that process\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of sulfasalazine for a patient with the NAT2 slow acetylator phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma cimetidine concentrations in a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C19 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"omeprazole\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf\", \"Content to Search\": \"Diplotype definitions corresponding to the CYP2C19 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should diphenhydramine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of anticholinergic side effects with tiotropium in individuals with specific CHRM variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"milnacipran\", \"Gene Name\": \"SLC6A4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR).\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"streptomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of entrectinib for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking acebutolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking acebutolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Which diplotypes define a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ibuprofen\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Diplotype definitions for the CYP2C9 poor metabolizer phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking nebivolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nebivolol\", \"Gene Name\": \"ADRB1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on the efficacy of nebivolol in patients with the ADRB1 Arg389Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2D6 enzyme in the metabolism of hydromorphone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Description of CYP2D6's role in hydromorphone metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should dimethyl fumarate dosing be adjusted for a patient with a specific variant in the HCAR2 (GPR109A) gene?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydromorphone in children with a CYP2D6 ultrarapid metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydromorphone\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for hydromorphone in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for felodipine in elderly hypertensive patients with known CYP3A4 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does CYP2C19 poor metabolizer status affect the plasma concentration of imipramine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"imipramine\", \"Gene Name\": \"CYP2C19\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Pharmacokinetic data on imipramine plasma concentrations in CYP2C19 poor metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 enzyme in the context of sotalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on sotalol efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is tolazamide contraindicated or should dosing be adjusted for a G6PD deficient individual?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tolazamide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Dosing protocol or contraindication for tolazamide in G6PD deficient individuals.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP3A4 enzyme in the metabolism of nirmatrelvir, and how is it inhibited by ritonavir?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended tramadol dose for a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"tramadol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Specific dosing recommendation or contraindication for tramadol in CYP2D6 ultrarapid metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking ofloxacin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ofloxacin\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with ofloxacin use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma buprenorphine concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"buprenorphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for buprenorphine stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target therapeutic plasma concentrations for gentamicin, and how are they affected by MT-RNR1 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"gentamicin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"Therapeutic drug monitoring ranges for gentamicin and any specific considerations for MT-RNR1 variant carriers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should amphotericin B dosing be adjusted for a patient with a specific variant in the AMB-binding ergosterol synthesis pathway?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"paromomycin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ABCG2 transporter in the efflux and bioavailability of imatinib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2B6 poor metabolizer phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomilnacipran\", \"Gene Name\": \"CYP2B6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for levomilnacipran in CYP2B6 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects with zaleplon in individuals with low-activity AOX1 variants?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended atorvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atorvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for atorvastatin in CYP3A5 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of oseltamivir for a patient with a CES1 G143E variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for praziquantel therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of developing Stevens-Johnson syndrome (SJS) when taking phenytoin for a patient with the HLA-B*15:02 allele?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"phenytoin\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf\", \"Content to Search\": \"Risk multiplier or incidence rate of SJS in HLA-B*15:02 carriers using phenytoin\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific PK/PD parameters to monitor for sevoflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sevoflurane\", \"Gene Name\": \"RYR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf\", \"Content to Search\": \"Pharmacokinetic or pharmacodynamic monitoring parameters for sevoflurane in the context of RYR1-MHS.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended sotalol dose for an individual with the GRK5 Gln41Leu polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for sotalol based on GRK5 Gln41Leu genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should clozapine dosing be adjusted for a CYP1A2 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of fluticasone for a patient who is a CYP3A4 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of betaxolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking propranolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using propranolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking venlafaxine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"venlafaxine\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using venlafaxine.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of nitrofurantoin for a patient with a specific variant in the nitroreductase gene (NfsA/NfsB)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there any therapeutic drug monitoring recommendations for oxcarbazepine based on HLA-B*15:02 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"oxcarbazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Therapeutic drug monitoring guidance for oxcarbazepine in relation to HLA-B*15:02 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How does the CYP2D6 enzyme metabolize amitriptyline to its active metabolite, nortriptyline?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amitriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Mechanism of CYP2D6-mediated metabolism of amitriptyline to nortriptyline\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking bisoprolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"bisoprolol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking bisoprolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking betaxolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking betaxolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nalidixic acid?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nalidixic acid\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Incidence rates or risk multipliers for acute hemolytic anemia with nalidixic acid use in G6PD deficient patients.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific recommendations for ribavirin use in patients with liver transplants based on their IFNL4 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ribavirin\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Guidance for ribavirin use in liver transplant recipients stratified by IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of severe diarrhea and rash with gefitinib in individuals who are CYP2D6 poor metabolizers?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the target plasma concentrations for teriflunomide (active metabolite) in a patient with a CYP2C9 intermediate metabolizer phenotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected plasma morphine concentrations in a patient with a COMT low-activity genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Therapeutic range or plasma concentration data for morphine stratified by COMT genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a defined therapeutic window for carbamazepine that changes based on HLA-B*15:02 status?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"carbamazepine\", \"Gene Name\": \"HLA-B\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf\", \"Content to Search\": \"Therapeutic drug monitoring values or plasma concentration ranges for carbamazepine in relation to HLA-B*15:02 status\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking sotalol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sotalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Risk multipliers or clinical data on heart failure outcomes with sotalol in patients with the GRK5 Leu41 variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperphosphatemia and serous retinal detachment with pemigatinib in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the target IC50 value for zanamivir against an influenza strain with a known NA genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Is there a difference in the clearance of peginterferon alfa-2b based on a patient's IFNL4 genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"peginterferon alfa-2b\", \"Gene Name\": \"IFNL4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf\", \"Content to Search\": \"Pharmacokinetic data on peginterferon alfa-2b clearance stratified by IFNL4 genotype\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which mesalazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mesalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of mesalazine-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended lovastatin dose for a CYP2C9 poor metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"lovastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Dose adjustment protocol for lovastatin in CYP2C9 poor metabolizers.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do CYP2C8 genotypes correlate with amiodarone clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should azathioprine dosing be adjusted for a TPMT intermediate metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"azathioprine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Dose adjustment protocol or percentage reduction for azathioprine in TPMT intermediate metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the primary metabolic pathway of guaifenesin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sulfasalazine\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for betaxolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"betaxolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for betaxolol in heart failure patients, adjusted for ADRA2C genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the CYP2C9 enzyme in the metabolism of piroxicam?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"piroxicam\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf\", \"Content to Search\": \"Description of CYP2C9's function in piroxicam's metabolic pathway.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of oxycodone?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of oxycodone for a patient with the ABCB1 3435C>T variant?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should valproic acid dosing be adjusted for a patient with a POLG1 mutation?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of systemic side effects with topical mometasone in individuals with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of developing hepatotoxicity (nodular regenerative hyperplasia) in a TPMT normal metabolizer on long-term thioguanine therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"thioguanine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Risk data for thioguanine-induced hepatotoxicity in TPMT normal metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking levomethadone?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"levomethadone\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for levomethadone in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking fentanyl?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Risk multipliers or incidence rates of adverse effects for fentanyl in patients with COMT high-activity genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking nadolol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Quantified risk data for adverse effects in CYP2D6 poor metabolizers using nadolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma zafirlukast concentrations in a CYP2C9 intermediate metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"acebutolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What OPRM1 variants are associated with altered morphine response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"morphine\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"List and description of OPRM1 variants and their corresponding functional impact on morphine response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for labetalol in patients with hypertension and a GRK4 polymorphism associated with altered response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK4\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dosing guidelines for labetalol in hypertensive patients, adjusted for GRK4 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What are the expected hematological changes in a G6PD deficient individual exposed to dimercaprol?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"dimercaprol\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Data on hematological parameters in G6PD deficient individuals after dimercaprol administration.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What HTR2A variants are associated with altered escitalopram response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"escitalopram\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"List and description of HTR2A variants and their corresponding impact on escitalopram response.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the role of the TPMT enzyme in the metabolism of cisplatin?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ciprofloxacin concentrations in a CYP1A2 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"amikacin\", \"Gene Name\": \"MT-RNR1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf\", \"Content to Search\": \"List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of clonidine for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the UGT1A9 enzyme in the glucuronidation of regorafenib?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the suggested therapeutic range for plasma ribociclib concentrations in a CYP3A4 rapid metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for alfentanil in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"alfentanil\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for alfentanil in cancer patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "Are there specific nortriptyline dosing guidelines for geriatric patients who are CYP2D6 ultrarapid metabolizers?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nortriptyline\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf\", \"Content to Search\": \"Geriatric dosing recommendations for nortriptyline in CYP2D6 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A6 genotypes map to acetaminophen glucuronidation phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do UGT1A9 genotypes map to fenofibric acid clearance phenotypes?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hypertensive crisis with procarbazine when tyramine-containing foods are consumed, based on MAO genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of peripheral edema with amlodipine in patients with reduced CYP3A4 function?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What genotypes define the COMT 'normal-activity' phenotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"sufentanil\", \"Gene Name\": \"COMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the GRK5 gene product in the context of labetalol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"labetalol\", \"Gene Name\": \"GRK5\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the expected clinical response to duloxetine in a patient with the HTR2A rs7997012 G/G genotype?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"duloxetine\", \"Gene Name\": \"HTR2A\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf\", \"Content to Search\": \"Pharmacodynamic data, such as remission rates, for duloxetine stratified by HTR2A rs7997012 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the threshold for 6-TGN concentration that is associated with an increased risk of toxicity from mercaptopurine?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mercaptopurine\", \"Gene Name\": \"TPMT\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf\", \"Content to Search\": \"Toxicity threshold for 6-thioguanine nucleotide concentrations\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should paroxetine dosing be adjusted for a patient with a COMT Val158Met polymorphism?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking fentanyl?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fentanyl\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Quantified risk or clinical evidence for reduced analgesic efficacy of fentanyl in patients with the OPRM1 A118G variant.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended propranolol dose for an individual with the ADRB2 Gly16Arg polymorphism?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"propranolol\", \"Gene Name\": \"ADRB2\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Dose adjustment protocol for propranolol based on ADRB2 Gly16Arg genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended ondansetron dosing adjustment for a CYP2D6 ultrarapid metabolizer?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"ondansetron\", \"Gene Name\": \"CYP2D6\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf\", \"Content to Search\": \"Dose adjustment protocol or alternative therapy for ondansetron in CYP2D6 ultrarapid metabolizers\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the mechanism by which mafenide causes oxidative stress leading to hemolysis in G6PD deficient individuals?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"mafenide\", \"Gene Name\": \"G6PD\", \"CPIC Guideline Name\": \"Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf\", \"Content to Search\": \"Biochemical mechanism of mafenide-induced oxidative damage to red blood cells in the context of G6PD deficiency.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should piperacillin-tazobactam dosing be adjusted for a patient with a specific variant in a renal transporter gene like OAT1/OAT3?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the recommended dose of granisetron for a patient who is a CYP2D6 poor metabolizer?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How do FCER1A genotypes correlate with omalizumab efficacy phenotypes in severe allergic asthma?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "How should linagliptin dosing be adjusted based on ABCB1 genotype?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for hydrocodone in pediatric patients with an OPRM1 variant associated with decreased receptor function?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"hydrocodone\", \"Gene Name\": \"OPRM1\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf\", \"Content to Search\": \"Dosing guidelines for hydrocodone in pediatric patients, adjusted for OPRM1 genotype.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What diplotypes define a CYP3A4 intermediate metabolizer for ibrutinib therapy?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What ADRA2C polymorphisms are associated with altered beta-blocker response?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"nadolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the CYP2C9 enzyme in the metabolism of simvastatin?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"simvastatin\", \"Gene Name\": \"CYP2C9\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Description of CYP2C9's role in simvastatin metabolism.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the function of the ADRA2C gene product in the context of atenolol therapy?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"atenolol\", \"Gene Name\": \"ADRA2C\", \"CPIC Guideline Name\": \"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf\", \"Content to Search\": \"Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with atenolol.\"}]"}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the increased risk of hyperbilirubinemia with nilotinib in individuals with reduced UGT1A1 function (Gilbert's syndrome)?"}, {"from": "Assistant", "value": "No CPIC guideline information available."}]}
{"system": "", "mask": "User", "conversations": [{"from": "User", "value": "What is the dosing recommendation for fluvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?"}, {"from": "Assistant", "value": "[{\"Drug Name\": \"fluvastatin\", \"Gene Name\": \"CYP3A5\", \"CPIC Guideline Name\": \"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf\", \"Content to Search\": \"Pediatric dosing adjustments for fluvastatin in CYP3A5 normal metabolizers.\"}]"}]}
